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1  INTRODUCTION 
Solid dosage forms such as tablets and capsules are the most popular drug delivery 
systems. Tablet and capsule dosage forms mainly contain active pharmaceutical ingredients 
and excipients [1]. The excipients may be diluents, binders, disintegrants, glidants and 
lubricants; lubricants are usually added in the final stages of mixing of the formulation 
components, prior to compression or encapsulation. Both tablets and capsules require 
lubricants in their formulations in order to reduce the friction between the powder and metal 
surfaces. The main function of lubricants is to prevent the adhesion of compacts to the 
surface of the punches, dyes or encapsulating tools used in pharmaceutical 
manufacture [2-4]. 
Magnesium stearate is the most widely used lubricant during tablet compaction and 
capsule filling operations in the pharmaceutical industry. It is preferred because of its low 
cost, high lubrication potential, relatively high melting point and chemical stability.  
 In industry, a number of problems arise in this context. It is important to investigate 
and resolve these problems. This is especially important in case of relatively new drug 
delivery systems, because there is not too much experience about their formulation. 
Medicated chewing gum has recently been included in the Pharmacopeias as a separate drug 
dosage form. New method of its production is not widespread yet. (Ph. Eur.) [5-7] 
 
2 AIMS 
 There are two main parts of this study. In the first part of my thesis I will present 
manufacturing problems which can be bound to the magnesium stearate (MgSt), and ways of 
solving them, discussing the composition of the products, the machines used and the 
technologies employed. Furthermore I will present my experiments with magnesium stearate, 
and the conclusions derived from the results. 
The second part of my dissertation is a formulation study of directly compressible 
chewing gum. That's not a widespread way of preparing a medicated chewing gum, and there 
are relatively few data and experience about this method. The role of MgSt is also very 
important in case of this drug form. This part includes all of the experimental results and the 
conclusions will be presented. 
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3 LITERATURE SURVEY 
3.1 Magnesium stearate 
 Magnesium stearate is a mixture of plant or animal origin, various magnesium salts of 
fatty acids. The fatty acid components are mainly stearic acid and palmitic acid; minor 
proportions are of other fatty acids. The fatty acid fraction contains at least 40.0% stearic 
acid. Magnesium stearate is the most widely used lubricant. In the pharmaceutical industry it 
is one of the most popular lubricants because relatively cheap. It has high lubricating 
capacity, relatively high melting point (117 – 150 °C) and it is chemically stable [8]. The 
effect of lubricant is well known: it has extremely small particle size therefore is able to form 
semicontinuous layer on the surface of the larger particles [9-11]. The effects as compared to 
other metallic salts of fatty acids derived from the fact that the metallic polar part of the 
molecule binds to the surface of particles, as a consequence of the apolar hydrocarbon 
molecules away from the surface of the dust is located in [12]. Consequently, a non-polar 
layer is formed between the particles and the various devices, such as crimping tools and 
capsules. Advantages and disadvantages of the use of magnesium stearate arising from the 
the non-polar layer can be experienced during compression and encapsulation. The 
hydrophobic nature frequently prevent the fluid ingress among to ingredients of capsule, so 
after the capsule shell dissolves in the gastrointestinal fluid, a capsule-shaped stopper often 
remains back, particularly if the capsule filling materials have been compressed by 
encapsulating machine [2]. Because of the described negative properties the minimum 
effective concentration is used: generally 0.5 - 3%. 
3.2 Calculation of the spreading coefficient 
 The lubrication effect is influenced by the mixing time and speed, the specific surface 
area and the spreading coefficient of the magnesium stearate. The spreading coefficient can 
be calculated via the free surface energy [13, 14], which is widely assessed indirectly from 
wettability measurements [15-17]. In the method of Wu and Brzozowski [18], the surface 
free energy is taken as the sum of the dispersive and the polar components. The surface free 
energies of solid materials can be determined by means of contact angle measurements, using 
two liquids with known polarities, which involve the solution of an equation with two 
unknowns: 
    
where Θ is the contact angle, γs is the solid surface free energy and γl is the liquid surface 
tension. If the surface free energies of the solid materials are known, the spreading 
 
(1) 
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coefficient (S) may be computed and the interactions between the two materials may be 
predicted. S is calculated as the difference between the adhesion work and the cohesion 
work. The two materials which interact can be two powders, a powder and a liquid (e.g. a 
core and a layering fluid), or any material and the equipment. 
 The spreading coefficient (S12) of one material (1) over the surface of another 
material (2) can be determined according to the following equation [19]: 
  
 If the spreading of the layering material on the surface of the core is insufficient, the 
efficiency of layering and the properties of the layer formed may be restricted. 
3.3 Energy dispersive X-ray microanalysis 
 Using X-ray microanalysis by them energetic properties it is possible to detect 
qualitatively and quantitively the elements in the samples. Its use spread to various areas of 
the industry, particularly in microelectronics, but recently studies in pharmaceutical 
technology shows that it can be applied equally suitable for the detection of contaminating 
elements and examine the distribution of elements as well. 
 In thisstudy a compact table-top energy dispersive X-ray fluorimeter (Figure 1) was 
used for the elemental analysis of magnesium. This technique is suitable for the direct 
measurement in drugs of the elements ranging from sodium to uranium [10, 20]. 
 
 
Figure 1: Energy dispersive X-ray fluorimeter 
 
 When a material is irradiated by the beam from an X-ray tube, its constituent atoms 
are excited. This causes them to emit X-ray fluorescence. Each element in the sample emits 
its own uniquely characteristic fluorescent radiation, with an intensity directly related to the 
concentration of that element in the material. This phenomenon is the basis of X-ray 
fluorescence spectrometry. (Figure 2)  
 
(2) 
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Figure 2: Fluorescence phenomena [21] 
 
 The fluorescence comprises discrete X-ray photons emitted at various (characteristic) 
energy levels. Photons of all energies are received simultaneously by the detector of the 
spectrometer and converted into a series of electrical signals, which are electronically 
amplified, processed and transformed into digital values. The digital values are stored in a 
multichannel analyzer, which separates them according to the photon energy levels. The 
result is the spectrum for the sample, which is further processed by the software to deliver a 
result calculated directly in terms of element concentrations [21]. 
 The aim of this study was to investigate the properties of magnesium stearate such as 
to test the effects of various parameters on the distribution of magnesium stearate on the 
surface of particles in mixtures. 
3.4 Medicated Chewing Gums 
 Chewing gum has been used world-wide since ancient times when man experienced 
the pleasure of chewing a variety of gum-like substances, such as tree resins, leaves, waxes 
and animal skins. Chewing gum has long been utilized. The eosin of the Sapodilla tree was 
used by the Mayan Indians for 1000 years, and after the Second World War the first 
synthetic chewing gums were developed [22-27]. 
 The dosage form or delivery system is critical for the success of a pharmaceutical or a 
food product. Today, chewing gum is undergoing new consideration as a drug delivery 
system; it provides patient benefit and compliance, and has new competitive advantages from 
technological and marketing aspects. The active pharmacutical ingredients (API) can be 
easily released from chewing gum into the salivary fluid within few minutes of chewing. 
Local and systemic effect can be reached by using this type of dosage form. The drug can be 
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absorbed through the oral mucosa or swallowed (gastrointestinal absorption). These 
absorption pathways are possible to introduce the active ingredient into the systemic 
circulation giving rise to a systemic effect. Drug can be easily permeated (e.g. BCS class I) 
from oral mucosa by the pressure created by the chewing action and absorbed directly via the 
buccal membrane avoids metabolism in the G.I tract and the first-pass effect of the liver; it 
might therefore be to administer a reduce dose in chewing gum compared to other oral 
delivery system. Therefore, ultimately patients will get quick relief. [5, 28-41] 
 Medical chewing gums are official as drug delivery systems in the Pharmacopoeias 
(e.g.:Ph.Eur. (1991) and USP). Medicated chewing gums are solid, single-dose preparations 
that have to be chewed but not swallowed. Chewing gums contain one or more active 
pharmaceutical ingredients (APIs) that are released by chewing (Ph.Eur.) [42]. Medicated 
chewing gum is intended to be chewed for a certain period of time, required to deliver the 
dose, after which the remaining mass is discarded. Chewing gum consists basically of a 
neutral and tasteless masticatory gum base and several non-masticatory ingredients, such as 
fillers, softeners, sweeteners, flavoring and texture regulating agents [42-43]. The gum bases 
currently used are mostly of synthetic origin and comprised of elastomers, resins, waxes, fats 
and emulsifiers. The elastomers are styrene–butadiene copolymers mixed with 
polyisobutene. The addition of rosin esters and polyvinyl acetate improves the texture, allows 
longer-lasting flavor and reduces the tendency of the gum to stick to the teeth. Other agents, 
such as glycerol monostearate and lecithin, act as emulsifiers and promote the uptake of 
saliva during chewing [44]. Powdered sugar and corn syrup were originally used as bulk 
sweeteners; nowadays, a mixture of sorbitol, xylitol, mannitol and aspartame is more 
commonly used in sugarfree, non-cariogenic gums and medicinal products [45-46]. 
Unfortunately, the thermal instability of many active ingredients (vitamins, vegetable 
extracts, etc.) precludes traditional chewing gum production methods because the 
temperature profiles associated with this type of production may reach 90°C [47]. 
 Chewing gums can be manufactured through melting processes, extrusion or direct 
compression. Recently, chewing gums produced by direct compression have been proposed 
[48-49]. This method has only been possible since the direct compressible gum-based 
products have appeared on the market (e.g. Health-in-Gum® [50]). Direct compression is a 
popular method in tablet manufacturing because it involves a comparatively short processing 
time, low labour costs, a small number of manufacturing steps, little demand for equipment 
and relatively simple process validation. With this conventional tablet compression 
technology, these chewing gums can include higher levels of active ingredients than in 
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traditional extruded gums; the lower temperature protects sensitive bioactive and 
phytochemical components and the lower moisture content improves the shelf-life of active 
molecules.  
 However, the most common drawback in direct compression of the gum base is that it 
sticks to the punches of the tableting equipment. This is due to the adhesive nature of the 
gum, the main component of the formulation; for this reason, the procedure is difficult and 
needs lower production speed and cooling operations in order to prevent tableting machine 
damage. Sticking and friction can be minimized through the use of lubricants, such as 
magnesium stearate. Forms of magnesium stearate with different specific surface areas are 
available commercially. Their lubrication effect depends on the specific surface area. 
Furthermore the tableting tools are kept at temperatures below 18°C; however, it should be 
noted that the temperature should not be so low as to interfere with the handling of medicated 
gums and tableting process. Thus, the temperature should be above 10–12°C.  
 Of course the examination of active pharmaceutical ingredients (API) release is really 
important in case of chewing gum tablets as well. For investigation of the dissolution of 
API’s from medicated chewing gum tablets, different apparatus have been developed. Till 
1999 only two apparatus/methods have been available [39, 51]. Then the chewing equipment 
applied was developed by Erweka GmbH, and described by Kvist et al [52]. Further 
descriptions of dissolution and chewing gum tablet investigations have been reported by 
Azarmi et al [53]. 
 The aim of this study was to examine production conditions of the medication 
chewing gum tablets, the compression parameters, the applicability of different type of 
magnesium stearates, the compressibility, the chewability and the drug release, which 
provide useful information for the industrial production. 
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4 SECTION I - THE EFFECTS OF MAGNESIUM STEARATE 
4.1 Manufacturing problems in pharmaceutical industry 
4.1.1 Background: Process validation, general descriptions 
I work as pharmatechnologist and my main project is performing process validations. 
The correct validation of pharmaceuticals, that is, the method of proof in accordance with 
GMP (Good Manufacturing Practice) principles, which can be demonstrated that a process, 
procedure, device, method, activity or system actually meets the specified  
requirements [54-59]. 
Pharmaceutical Technology Department carried out with the aim of validation of a 
particular product: The objective of these validations is to assure that manufacturing process 
according to methodology described in the Manufacturing Validation Procedures (MVP) of 
the product is capable for reproducible manufacture of the product that complies with all in-
process, validation and finished product specifications. The quality of these product 
conforms to the in-process (IPC), validation and final product requirements. 
Typically validation process of solid dosage forms (tablets, capsules) is performed. 
During the tableting or encapsulation of granules speed validation is performed. These 
validations should be performed by prospective manner with production of at least 3 
successive batches in the commercial batch size. The compression/encapsulation is started at 
the low speed according to MVP of product and not less than (1/10th of the batch) are 
compressed, than the high speed (the practicable highest) is set up at which the IPC tests are 
within the limits of acceptance criteria. Not less than (1/10th of the batch) are compressed / 
encapsulated at that speed as well. After this running the target speed optimum selected is set 
up and the compression / encapsulation continued. These validations mainly should be 
performed by prospective manner with production of at least 3 successive batches in the 
commercial batch size. All parameters tested should be within the limits of acceptance 
criteria. In example the dissolution profil of the samples must be similar to the profile of 
biobatch wich is the test batch used in the biostudy to demonstrate bioequivalence, or used in 
the biowaiver to demonstrate similarity, compared to the comparator product. The data will 
be evaluated to verify that the results of the total batch to be consistently within the limits, 
based on the samples tested. Process Validation Report is prepared by Pharmaceutical 
Technology Department. 
During validation work of different products various dissolution problems were 
observed. In some cases magnesium stearate as an excipient was the cause of these problems. 
In case of some products the specific surface area of magnesium stearate and the 
homogenization time are really important parameters. We met these phenomena in case 
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different manufacturing techniques and different solid dosage forms. These will be explained 
below, covering the composition, manufacture of machinery and technology used for these 
problems and their solutions. 
4.1.2 Product I details  
4.1.2.1 Short display, magnesium stearate related parameters 
 This product is a film-coated tablet which is manufactured using wet granulation; 
compression, and then coating. Magnesium stearate is added to the granule just before final 
blending.  
The final blending time: 5 minutes 
Type of magnesium stearate applied at the beginning of the validations: with large specific 
surface area (6 – 10 m²/g) (Producer: Peter Greven Nederland, Venlo, Netherlands) 
The amount of magnesium stearate in the formulation: 1% 
4.1.2.2  Materials 
The composition of the Product I can be seen in Table 1 
Table 1: Materials used for the manufacture of the Product I 
Composition 
Name Quality 
Active pharmaceutical ingredient (API) Ph.Eur. 
Lactose monohydrate (pulvis) Ph.Eur. 
Starch pregelatinised (Starch 1500) Ph.Eur. 
Hypromellose (15 MPAS) Ph.Eur. 
Croscarmellose sodium Ph.Eur. 
Silica colloidal anhydrous Ph.Eur. 
Magnesium stearate (Peter Greven) (1%) Ph.Eur. 
Water purified Ph.Eur. 
Opadry, II 33G28707 white in-house 
 
4.1.2.3 Methods 
4.1.2.3.1 Qualified equipments used for manufacturing  
A list of equipments used for the manufacture of the product in Table 2 
Table 2: Equipments 
High shear mixer: LÖDIGE MGT 400 
Fluidization dryer: GLATT WST CD-60 
Oscillation granulator: FREWITT. 
Blender/tumbler, (Flo-bin 750 litre) 
Rotating compression machine with deduster, FETTE P2000/II, P2090  
Metal checker 
Coating equipment, GLATT GC-1250  
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4.1.2.3.2 Brief Description of manufacturing process  
The manufacturing process is demonstrated in Figure 3. 
 
Lactose monohydrate
API
Starch, pregelatinised
Hypromellose
Mixing
(High shear mixer)
Water purified
Fluid bed dryer
Oscillating granulator
Croscarmellose sodium (Portion II)
Silica colloidal anhydrous Tumbler blender
Magnesium stearate
Sieve
Croscarmellose sodium (Portion I) Sieve
Sieve
Rotary press machine
VI. COMPRESSION
Spray coating 
machine 
Opadry 
Water purified
VII. COATING
Tumbler blender
I. INITIAL BLENDING
II. GRANULATION
IV. INTERMEDIATE BLENDING
V. FINAL BLENDING
III. DRYING, MILLING
 
Figure 3: Flow chart – Product I 
4.1.2.4 Description and the solving of the manufacturing problem  
 During validation process dissolution tests should be performed, including film-
coated tablets and corpus case, which results must comply in the pre-defined specifications 
(Biobatch profile). In case of generic products in the development stage, comparative 
dissolution study had been carried out to confirm that generic product and the product 
manufactured by the originator product are in equivalence.  
The dissolution tests were carried out as follows (a photometric measurement): 
Table 3: Dissolution conditions 
Device: according to Ph. Eur. (paddle stirrer) 
Dissolution medium: 0.1 M HCl 
Dissolution medium temperature: 37 ± 0.5 ° C 
Dissolution medium volume: 900 ml 
Sample time point: 10, 20, 30, 45 and 60 minutes 
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The validation process also conducted a number of occasions for various reasons, 
which were mainly carried out in connection with registrations for changes. During the initial 
validation lower dissolution results were occurred (Figure 4), but only in few cases were out 
of specification result.  
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Figure 4: Dissolution profiles of the Biobatch and Validation batch 
 
In this context, various changes were proposed in the production process. Initially, we 
reduced the core hardness, to decrease the disintegration time and this is abbreviated to 
accelerate the dissolution rate. The binder addition time and the granulation time were 
reduced to get “weaker” granule. The coating parameters have been also modified but mainly 
it was the aim to achieve better appearance. The dissolution profiles significantly did not 
improved due to these changes then it was decided to change the lubricant  
from the large surface area (6-10 m² / g – Peter Greven) magnesium stearate to the lower 
specific surface area (1.5-3.5 m² / g - Undesa) magnesium stearate with "coarser" particle. 
After this modification the dissolution profile was still not perfect, but it was not a lubricant 
failure, the cores have been pressed harder because continuous sticking problems. This 
problem has been solved by the following corrections: the granulation end point and the 
granulation time were modified, furthermore power end point limit was determined in the 
granule recipe and the loss on drying (LOD) specification of dried granule was modified. 
 These changes clearly show that the product quality highly depends on numerous 
manufacturing parameters and the properties of excipients as well. 
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4.1.3 Product II details  
4.1.3.1 Short display, magnesium stearate related parameters 
 The second product is an uncoated tablets prepared by fluidization granulation. The 
magnesium stearate was added to the granules directly before final blending. 
The final homogenization time: 1 minute 
The initially used Magnesium Stearate: with high specific surface area (6-10 m² / g) 
(Manufacturer: Peter Greven Nederland, Venlo, The Netherlands) 
The amount of magnesium stearate in the formulation: 1% 
 
4.1.3.2 Materials 
The composition of the Product I can be seen in Table 4 
Table 4: Materials used for the manufacture of the product 
Composition 
Name Quality 
Active pharmaceutical ingredient (API) Ph. Eur. 
Lactose monohydrate  Ph.Eur. 
Potato starch Ph.Eur. 
Povidone K 25 Ph.Eur. 
Denatured alcohol USP+BP. 
Silica, colloidal anhydrous Ph.Eur. 
Magnesium stearate Ph.Eur. 
4.1.3.3 Methods 
4.1.3.3.1 Qualified equipments used for manufacturing  
Table 5: Equipments 
 
GLATT Granulation suite (high shear mixer with fluid bed drier, rotating 
impeller with screen “cheese grater” 1.5 mm 
RUSSELL vibratory sieve (30 mesh, 40 mesh) 
Blender/tumbler, (Flo-bin 750 litre) 
Rotating compression machine with deduster, FETTE P2000/II, P2090  
Metal checker 
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4.1.3.3.2 Brief Description of manufacturing process 
The manufacturing process is demonstrated in Figure 5. 
 
 
Figure 5: Flow chart – Product II 
 
4.1.3.4 Description and the solving of the manufacturing problem 
In case of one validation batch of this product we got out of specification dissolution 
result at 45 minutes sampling time (batch No.: Batch 6). Predetermined specification limit: 
not less than 90 % of the labeled amount must be dissolved within 45 minutes. This value 
was lower in case of this batch.  
The dissolution tests were carried out as follows (a photometric measurement): 
Table 6: Dissolution conditions 
Device: according to Ph. Eur. (paddle stirrer) 
Dissolution medium: Water purified 
Dissolution medium temperature: 37 ± 0.5 ° C 
Dissolution medium volume: 900 ml 
Sample time point: 45 minutes 
 
After the development phase in case of the first validation batch (Batch 1) similar 
problems were observed, but it could be eliminated by final blending time reduction with 
maintain adequate homogeneity. 3 minutes final blending time used for experimental 
validation batches and the first validation batch was reduced to 1 minute during the further 
manufacturing. New validation was started with manufacturing further validation batches. 
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Similar problem was not observed. The manufacturing was performed according to the 
documentation, which was approved by the developers. 
 Based on the review of manufacturing documents it can be stated that the API and other 
excipients forming the product have been weighed in appropriate quantity and quality. Using 
the required parameters there was no problem during fluid granulation. The drying took 
shorter than the planned time. The loss on drying still conformed to the specification. The 
homogenization times were consistent with the requirement. The manufacturing procedure 
did not contain extra comments on granulation phase.  
The following in process parameters were measured during compression: average 
resistance to crushing (alias crushing strength or hardness), thickness, friability, 
disintegration time and average weight. The measurements were carried out in appropriate 
intervals and all results conformed to the pretermined acceptance criterias, although the 
measured disintegration times were close to the upper limit of the specification have 
(specification: < 10 minutes, actual: from 7 minutes 45 seconds to 9 minutes 10 seconds). 
The list of disintegration times is in table 4. 
Validation tests (Table 7) provided for in the protocol is carried out correctly. 
Table 7: Validation tests 
sieve analysis 
bulk and tapped density granule physical tests: 
flowing properties 
average weight 
resistance to crushing 
friability 
disintegration time 
tablet physical tests: 
assay tests 
 
The sieve analysis results show (Table 8) that the granule has “finer grain” than in case 
the previous batches. Based on the validation test results (Table 9) it is concluded that the 
hardness values are similar to the previous two batches, and close to the lower limit of the 
specification. The disintegration times, although were within specification, but were higher 
than the results of previous batches (required: not more than 10 mins, actual: 7.8-8 minutes). 
The active substance contents of tablets were appropriate: 98.8%, 99.1%, and 100.4%.  
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Table 8: Sieve analysis results 
Batches 1st validation 
batch 
2nd validation 
batch 
3rd validation 
batch 
4th validation 
batch 
5th validation 
batch 
6th validation 
batch 
Batch number Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 
Sieve analysis       
Sieve size (µm)      
1000 
0.03 0.01 0.06 0.01 0.00 0.00 
Sieve residue (%) 710 0.32 0.10 0.31 0.54 0.02 0.00 
 500 1.65 1.57 1.51 1.51 1.28 1.00 
 355 3.26 2.36 3.70 3.20 1.98 4.60 
 250 9.42 10.21 10.03 9.53 9.00 9.60 
 106 49.06 54.11 42.11 41.53 50.33 36.00 
 53 30.11 25.17 27.93 31.07 25.99 20.00 
 0 5.98 6.14 14.41 12.39 11.37 28.60 
Bulk density (g/cm³) 0.663 0.648 0.667 0.699 0.639 0.650 
Tapped density (g/cm³) 0.780 0.762 0.785 0.817 0.765 0.770 
Flowing time ( second) 2 2 2 2 2 1 
 
Table 9: Rewiew of the main parameters in case of the first 6 validation batches 
Batches 1st validation 
batch 
2nd validation 
batch 
3rd validation 
batch 
4th validation 
batch 
5th validation 
batch 
6th validation 
batch 
Batch number Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 
Magnesium 
stearate 
Specific surface 
area (m2/g) 
6.8 m2/g 7.6 m2/g 7.6 m2/g 7.5 m2/g 6.2 m2/g 8.3 m2/g 
Drying time 
after fluid 
granulation  
14 mins 9 mins 16 mins 14 mins 14 mins 13 mins 
Final blending 
time(min) 3 mins 1 min 1 min 1 min 1 min 1 min 
Dissolution (%) 
(sampling at 45 
minutes) 
82 % (average) 91 % (average) 92 % (average) 98 % (average) 95 % (average) 
62 % (minimum) 
78 % 
(maximum) 
Compr. 
begin 6.6 
Compr. 
begin 4.5 
Compr. 
begin 4.9 
Compr. 
begin 6.0 
Compr. 
begin 5.5 
Compr. 
begin 5.3 
Compr. 
middle 5.7 
Compr. 
middle 5.2 
Compr. 
middle 5.1 
Compr. 
middle 5.8 
Compr. 
middle 5.7 
Compr. 
middle 4.9 
Resistance to 
crushing 
Specification: 
 
Average: 5-8 kp Compr. 
end  6.5 
Compr. 
end  5.4 
Compr. 
end  4.9 
Compr. 
end  5.9 
Compr. 
end  6.4 
Compr. 
end  5.2 
Disintegration 
time during In 
process  tests, 
(min, sec.)  
specification: 
<10 minutes 
9’00” – 9’45” 5’00” – 7’00” 5’00” – 5’30” 7’00” – 7’30” 6’00” – 7’00” 7’45” – 9’10” 
Compr. 
begin 6.9 
Compr. 
begin 4.5 
Compr. 
begin 3.6 
Compr. 
begin 6.0 
Compr. 
begin 4.0 
Compr. 
begin 7.8 
Compr. 
middle 6.4 
Compr. 
middle 4.3 
Compr. 
middle 5.2 
Compr. 
middle 6.1 
Compr. 
middle 4.1 
Compr. 
middle 7.8 
Disintegration 
time (min) 
during 
Validation tests,  
specification: 
<10 minutes 
Compr. 
end  6.3 
Compr. 
end  5.3 
Compr. 
end  5.0 
Compr. 
end  6.3 
Compr. 
end  4.6 
Compr. 
end  8.0 
Based on these results, it was concluded that on the surface of relatively small granular 
particles the larger surface area of magnesium stearate formed a hydrophobic layer, resulting 
elongated disintegration time and slower dissolution of the API. The fluidized granulation is 
a well controlled manufacturing process, however, in routine production it can occur that 
"fine-grained" granules form. This phenomenon mainly comes from the properties of API. 
To overcome this problem, we suggested the use of a magnesium stearate with smaller 
specific surface area, preventing the further dissolution problems. After this modification 
dissolution problem was no longer occured and the disintegration time was greatly reduced. 
The problem was successfully solved. 
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4.1.4 Product III details  
4.1.4.1 Short display, magnesium stearate related parameters 
This product is a capsule containing 2 different API and manufactured by wet 
granulation. The speciality of this production technology is that the two active ingredients are 
in different phases. First active ingredient is in the internal phase which made by wet 
granulation and the other active ingredient is mixed to the materials after sieving as a part of 
the external phase. Application of this technology due to the moisture-sensitive active 
ingredient added to the external phase after wet granulation. The magnesium stearate was 
added directily before the final blending phase after a brief bag blending (in Polyethylene 
bag). 
Mannitol and Cellulose are fillers in composititon to provide the necessary load mass. 
Povidone is binder which is often used in wet granulation. Talcum is in the composition to 
improve the granule flow properties, while Magnesium stearate reduces the adhesion/friction 
between the granule and the used equipments. 
The final homogenization time: 5 minutes 
The initially used Magnesium Stearate: with high specific surface area (6-10 m² / g) 
(Manufacturer: Peter Greven Nederland, Venlo, The Netherlands) 
The amount of magnesium stearate in the formulation: 1% 
4.1.4.2 Materials 
Table 10: Materials used for the manufacture of the product 
Composition 
Name Quality 
Active pharmaceutical ingredient (API) I Ph.Eur. 
Active pharmaceutical ingredient (API) II Ph.Eur. 
Cellulose, microcrystalline Ph.Eur. 
Mannitol Ph. Eur. 
Povidone K30 Ph.Eur. 
Talc Ph.Eur 
Magnesium Stearate Ph.Eur. 
Water purified Ph.Eur. 
Hard gelatin capsules In house 
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4.1.4.3 Methods 
4.1.4.3.1 Qualified equipments used for manufacturing  
A list of equipments used for the manufacture of the product in table 11. 
Table 11: Equipments 
Granulation suite Diosna CCS600(II.): high shear mixer, fluid bed dryer, 
(Comil, 1.0 mm „cheese” greater) 
Russell vibratory sieve (20, 40 mesh) 
Blender, Tumbler (Flo-bin 750L) 
Capsule Filling machine 
Weight sorter 
Capsule polishinig machine  
Metal detector 
 
4.1.4.3.2 Brief description of manufacturing process 
The manufacturing process is demonstrated in Figure 6. 
 
Figure 6: Flow chart – Product III 
4.1.4.4 Description and the solving of the manufacturing problem 
During process validation not expected dissolution problems were observed. The aim 
was to explore the cause of these problems and solve them, because these phenomena were 
not observed during development. Based on the good granule homogenity test results after 
the first validation batch (Batch 1) we continued the validation with the second batch 
manufacturing (Batch 2). The granule productions were in line with expectations. After 
granulation the granules has been charged in capsule, and the associated speed validation was 
performed. The encapsulation of the two batches was planned in same date. The 
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encapsulation was started at the low speed (40 300 capsules/hour) according to 
Manufacturing validation procedure  and not less than 50,000 capsules (1/10th of the batch) 
were encapsulated, then the practicable highest speed (50 400 capsules/hour) was set up at 
which the IPC tests were  within the limits of acceptance criteria. Not less than 50,000 
capsules (1/10th of the batch) were encapsulated at that speed as well. After this running the 
target speed optimum selected were  set up and the encapsulation continued. This speed was 
equal to the high speed (50 400 capsules / hour) value. After the in-process tests the 
validation and final product (release) tests had been started. The validation studies have not 
been finished completely because we got not conformed dissolution results which were 
confirmed by the results of the Chemical Control Department. The required validation tests 
and measured results are in table 12. 
Table 12: Validation tests and results 
Parameters Ch.: Batch 1 Validation test results Specifications 
Average weight,  
Uniformity of mass  Not tested 
Percentage deviation NMT 
7.5 % from the theoretical 
weight 
Assay 
-API 1 
-API 2 
Not tested 
95,0 – 105,0 % 
(acceptance criteria Ph. 
Eur.) 
 API 2 API 1 
Low speed 2,7 3,4 
High speed 2,9 5,0 
Target speed beginning 5,0 2,9 
Target speed beginning 3,4 3,4 
Uniformity of 
Dosage Units(by 
content 
uniformity) 
- API 1 
- API 2 Target speed beginning 6,1 8,0 
Conforms to the current 
Ph.Eur  
AV value NMT 15,0 
 API 2 API 1 
Low speed 98 (96, 101) 101 (99, 102) 
High speed 96 (91, 101) 74 (65, 86) 
Target speed beginning 97 (95, 99) 78 (74, 80) 
Target speed beginning 95 (91, 98) 84 (70, 93) 
Dissolution 
average (min, max) 
(%) 
- API 1 
- API 2 
Target speed beginning 65 (55, 71) 33 (29, 37) 
NLT 75% (Q) of the 
labelled amount within 45 
minutes 
 API 2 API 1 
Low speed similar similar 
High speed not similar not similar 
Target speed beginning not similar not similar 
Target speed beginning not similar not similar 
Dissolution profile   
- API 1 
- API 2 
Target speed beginning not similar not similar 
It must be similar to the 
profile of the Biobatch  
 
The dissolution tests were carried out as follows (a photometric measurement): 
Table 13: Dissolution conditions 
Device: according to Ph. Eur. (paddle stirrer) 
Dissolution medium: Water purified 
Dissolution medium temperature: 37 ± 0.5 ° C 
Dissolution medium volume: 900 ml 
Sample time point: 5, 10, 15, 20, 30 and 45 minutes 
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The samples filled at low speed show good dissolution results. The dissolution 
conforms to the specification. The expectation for the dissolution profile similarity with the 
dissolution profile of the referent product (Biobatch) also met. 
The samples at high speed and the further samples showed continuously worsening 
results. The Figure 7 and 8 show clearly this progress.  
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Figure 7: Dissolution profile of API 1  
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Figure 8: Dissolution profile of API 2  
It can be observed that the API 1 in the internal phase shows lower dissolution than 
the API 2 in the external phase. This phenomenon can be explained by binding forces within 
the granule particles which caused the delayed release of the drug. 
 In case of the second batch (No.: Batch 2) we examined the low speed samples 
because these samples has been already showed low dissolution values. At 45-minute 
sampling the dissolution value was 62 % in case API 2 and 30 % in case API 1 instead of the 
80 % requirement.  
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4.1.4.4.1 Investigation 
It was observed that in case of the insufficient samples whole capsules (which do not 
disintegrate) remained in the dissolution vessel. The center of the capsules was not wetted 
(Figure 9) after loosening the capsule shell. It is assumed that the surface of the granulate 
particles become hydrophobic during filling, thereby inhibite dissociation of active 
ingredients. Hydrophobicity acting proves that the surfactant (Tween ® 20) which was added 
to the dissolution medium can accelerate the fluid entering the interior of filled granule so 
facilitate its disintegration and increase the degree of dissolution of the active ingredients. 
 
Figure 9: Whole capsule and not dissolved filled granule at the bottom of the dissolution 
vessel 
 Additional dissolution study started with capsules filled granule by hand. In the 
course of the experiment we modelled the granule filling strength to capsule shell. The 
granule has been loosely sprinkled into the capsule shells and in other case the granule was 
pressed into capsule shells using the greatest possible force. Using the two different charging 
methods the dissolution results conformed to the specification. With this evidence, the 
granule remained in the dissolution medium does not depend on the degree of filling 
strength. The release also spread over the surface of granules medium migration. The granule 
sprinkled on the surface of the dissolution medium also showed an appropriate dissolution 
results. 
The granules sampled in various phases of encapsulation show different behavior if 
these were sprinkled on the surface of the dissolution medium. During the examination of 
inproper dissoluted capsule fillings it was found that the filling forms non-wettable, oily 
layer on the surface charge of the dissolution medium. (Figure 10) 
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Figure 10: Non-wettable layer on the surface  
 
In contrast, the non-filled granules and the filling of well dissolved capsules contact 
solution quickly, almost instantaneously. (Figure 11) We used this test as an addititonal IPC 
test during further validation. Using this method it was easy to detect any change during 
encapsulation.  
 
Figure 11: The behaviour of the easily dissoluted granule 
 
The addditional test was carried out as follows: 
 To do this, we used a different filling of appropriate and inappropriate behavior in 
release capsules. The essence of the simplified test, the capsule filling of the liquid surface 
scattering, the visual observation of, the instrument can be approximated by numerical 
analysis results. The rapid test was 400 ml beaker was carried out under the following 
conditions: 
Table 14: Dissolution conditions for visual observations 
Dissolution medium: Water purified 
Dissolution medium temperature: room temperature 
Dissolution medium volume: 300 - 350 ml 
 
If the full charge falls to the bottom of the vessel in 1 minute, and does not form a 
film-like layer on the surface of the medium, the value and the dissolution profile of the 
predicted characteristic is appropriate. When wetted (into the medium) over a period  
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of 1-5 minutes, the dissolution specifications are near unity, but running in a flat curve has 
been mentioned. If the granule is only slightly or not at all wetted (that stated for 5 min) and 
the medium surface to form a permanent film on the filled capsule dissolution value will not 
meet the requirements. 
 
Subsequently, a granule batch was produced in a pilot scale. The granule was 
capsulated by two different encapsulating machines. Relative low speed was used to prevent 
friction. 
The capsules were sampled in every 30 minutes to make the test mentioned above. 
After starting encapsulation of the granules the disc temperature continued to rise and 
the solving after nearly 3 hours showed a deviation. Based on our experience, it was 
concluded that the over 26-28 º C the final blend became more hydrophobic (Table 15). 
Table 15: Results of visual tests using high specific surface area MgSt 
Bosch type equipment 
Batch: 0030808 Solving Temperature (°C) Comment 
conforms 24.6 start of encapsulation 
not conforms 25.5 (+3 hours) visible differents 
not conforms 26.0 (+ 8 hours) the granule is not solved 
not conforms 25.9 (+ 12hours) stop 
Macofar type equipment 
Ch: 0030808 Solving Temperature (°C) Comment 
conforms 22.5 start of encapsulation 
still conforms 26.2 (+3 hours) visible differents 
not conforms 28.2 (+ 8 hours) the granule is not solved 
not conforms 29.8 (+ 12 hours) stop 
 
Summarizing the experience we came to the conclusion that the high surface area of 
magnesium stearate used in the product need to replace a lower rate (Table 16), thus reducing 
the chances of particles coating by MgSt. The change has successfully solved the previous 
solving/dissolution problems. 
Table 16: Datas of different MgSt-s based on Certificate of Analysis by the manufacturers  
Specific surface are Magnesium Stearate (Peter Greven) 
Magnesium Stearate 
(UNDESA) 
Manufacturer specifications 6 – 10 m2/g 1,5 – 3,5 m2/g 
Actual values 9,2 m2/g 2,5 m2/g 
According to the production technology the granulation process was performed in the 
same manner till the internal phase manufacturing and then it was homogenized with the 
external phase, using alternative types of magnesium stearate (batch number: Batch 3). The 
granules are also encapsulated using two different encapsulation machine. During the 
encapsulation at all times adequate dissolution was observed by visual observation  
(Table 17) and then measured from the product. (Figure 12 and 13) 
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Table 17: Results of visual tests using lower specific surface area MgSt 
Macofar type equipment 
Ch: Batch 3 Solving Temperature (°C) Comment 
conforms 20.3 start of encapsulation 
conforms 26.1 (+ 4 hours) critical temperature 
conforms 27.2 (+ 7 hours) stop 
Bosch type equipment 
Ch: Batch 3 Solving Temperature (°C) Comment 
conforms 24.6 start of encapsulation 
conforms 25.3 (+ 2 hours) high speed 
conforms 26.1 (+ 3 hours) critical temperature 
conforms 27.6 (+ 5 hours) stop 
Temperature increasing was observed as during the encapsulation of previous batch 
but the product quality was not gone wrong. (see on table 17) 
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Figure 12: Dissolution profile of API 1 
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Figure 13: Dissolution profile of API 2 
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The dissolution problem occurred during the validation process have been succefully 
solved changing the type of MgSt based on the experience of experimental tests. The cause 
of the phenomenon is that the MgSt partially melted on the surface of the particles (which 
depends on the temperature, the degree of friction and the duration of encapsulation) and that 
made a hydrophobic layer. 
4.2  Investigation the effect of magnesium stearate  
Based on the experiences mentioned above (Industrial experiences) further 
examinations of properties of magnesium stearate were started. 
4.2.1 Materials 
 Two types of magnesium stearate were used as lubricant, with different specific 
surface areas: 8-10 m2/g (Peter Greven Nederland, Venlo, The Netherlands) and 2.5 m2/g 
(Undesa, Union Derivan, S.A., Barcelona, Spain) 
 The other materials applied were API 1, API 2 (Ph.Eur.) and granule contained both 
active ingredients. 
4.2.2 Methods 
4.2.2.1 Blending 
 The granules were mixed separately with 1% of the two types of magnesium stearate 
in a Turbula mixer (W.A. Bachofen Maschinenfabrik, Switzerland). The two mixtures were 
blended in two ways to prepare samples for examinations: 
(a) at a fixed blending speed of 25 rpm for various times (2, 5, 8, 10 and 15 min), or  
(b) at various blending speeds (25, 50, 75 and 90 rpm) for a fixed time of 5 min. 
4.2.2.2 X-ray fluorescence analysis 
 Measurements on the samples were made with a Philips MiniPal PW 4025 (MiniPal, 
Philips Analytical, Almelo, The Netherlands) energy dispersive X-ray fluorescence analyser. 
During the measurements, the conditions applied were 4 kV, 1000 A and 1 bar He purge. 
The samples were measured for 600 s and the measurements were repeated in triplicate for 
each sample. The concentration of Magnesium was calculated by means of linear calibration 
(r2= 0.9980) from the intensities of the K
 
shell of the detected radiation. The K value of 
Magnesium occurs at 1.253 keV. (Figure 14) 
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Figure 14: Energy dispersive spectrum of Mg. 
4.2.2.3 Morphological study 
 The surfaces of the samples were tested with a scanning electron microscope (SEM) 
(Hitachi S4700, Hitachi Scientific Instruments Ltd., Tokyo, Japan). A sputter coating unit 
(Polaron E5100, VG Microtech, UK) was used to charge the surfaces for the SEM 
measurements. The air pressure during the analyses was 1.3 – 13 mPa. 
4.2.2.4 Measurement of contact angle 
 Contact angles were measured on flat comprimates 12 mm in diameter, compressed 
with a hydraulic press (Röltgen GmbH & Company KG, Sollingen, Germany) at 1 MPa from 
the bulk materials (API 1, API 2, granules and magnesium stearate). 
 An automatic syringe was used for the dropping, and circle fitting was applied to 
determine the contact angles formed on comprimates prepared from different samples. The 
test fluids were distilled water and diiodomethane (Merck KGaA, Darmstadt, Germany). In 
the case of water, the drop volume was 10 µl, while in the case of diiodomethane, it was 3 µl. 
The advancing contact angles were measured. According to Ström [60], the dispersion 
component of the surface tension is 21.8 mN/m for water and 50.8 mN/m for diiodomethane, 
while the polar component of the surface tension is 51.0 mN/m for water and 0.0 mN/m for 
diiodomethane. 
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4.2.3 Results and discussion 
 The SEM pictures showed that the magnesium stearate with the higher specific 
surface area (Peter Greven) (Figure 15) was evenly distributed over the granule surface, 
while the magnesium stearate with the lower specific surface area (Undesa) (Figure 16) 
exhibited enrichment on the surface of the particles. The difference in grain size between the 
two types of magnesium stearate was clearly visible. 
   
Fig. 15:Distribution of Mg-stearate   Fig. 16:Distribution of Mg-stearate 
with the higher specific surface    with the lower specific surface  
area on the surface of the granules   area on the surface of the granules 
 
 The samples were examined by X-ray fluorimeter. At constant blending speed, with 
variation of the duration of blending, both type of magnesium stearate revealed magnesium 
concentration was the highest at a duration of 8 min (Figure 17). This phenomenon 
demonstrates that the covering of the particles by magnesium stearate is the highest at this 
time. After longer mixing time an overmixing can be observed.  
 It was additionally seen, that the magnesium stearate with the lower specific surface 
area resulted higher magnesium concentrations. This is in accordance with the visual 
observations (Figs 15 and 16), that the particles containing magnesium stearate with the 
higher specific surface area formed a thinner, but uniform layer. 
 When the blending was performed for a fixed period of time at differetnt blending 
speeds, it was found that the highest magnesium content was measured at 25 rpm for both 
forms of magnesium stearate (Figure 18), higher speed again leadin to overmixing. The 
magnesium stearate layer was thinner, but further increase of the speed did not cause any 
change in the homogeneity during 5 min. 
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* n=2, SD: Not more than (NMT) 5 % 
Figure 17: Influence of blending time at blending speed of 25 rpm 
on the distribution of magnesium on the surface of particles. 
 
 
* n=2, SD: Not more than (NMT) 5 % 
Figure 18: Influence of blending speed on the distribution of magnesium  
at a blending time 5 min. 
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 It is well known that the lubrication effect of magnesium stearate depends on its 
spreading ability on the surface of the particles. The spreading coefficient can be calculated 
via on the wetting contact angles. From these data, it is possible to calculate the total surface 
free energy, its polar and disperse parts, and the adhesion work. The data are presented  
on Table 18. 
Table 18: Parameters of surface properties of particles 
1st material 2nd material SE1 (mN/m) 
Sd1 
(mN/m) 
Sp1 
(mN/m) 
SE2 
(mN/m) 
Sd2 
(mN/m) 
Sp2 
(mN/m) 
Wa 
(mJ/m2) 
S1,2 
(mN/m) 
API 1 22.68 22.68 0 84.87 49.05 35.82 62.04 16.68 
API 2 22.68 22.68 0 82.85 47.10 35.75 61.23 15.87 
Mgst 
(high spec. 
surface area) 
Granule 22.68 22.68 0 82.10 48.28 33.82 61.72 16.36 
API 1 32.18 27.93 4.25 84.87 49.05 35.82 86.38 22.02 
API 2 32.18 27.93 4.25 82.85 47.10 35.75 85.33 20.97 
Mgst 
(small spec. 
surface area) Granule 32.18 27.93 4.25 82.10 48.28 33.82 85.88 21.52 
Note: SE=total surface free energy, Sd=disperse part of free energy, Sp=polar part of free 
energy, Wa=adhesion work, S12=spreading coefficient  
 
 It can be seen from the data, that API 1 and API 2 have high surface free energies, 
and their characteristics strongly influence the surface properties of the granules. Both types 
of magnesium stearate have much lower surface free energies, but it is noteworthy that, for 
the magnesium stearate with the higher specific surface area, the polar part is zero, and the 
apolar nature therefore dominates. This affects the value of the spreading coefficient. Since 
the magnesium stearate with the higher specific surface area is totally apolar it has fewer 
binding points on the surface of the particles, whereas the magnesium stearate with the lower 
specific surface area can also bind to polar binding points. In this case, the use of magnesium 
stearate with the lower specific surface area is more advantageous. 
 Since the spreading coefficient value (S12) is positive, magnesium stearate  
(material 1) spreads on the surface of the other components (material 2). The more positive 
S12, the better is the spreading. It must be noted that the spreading of the magnesium stearate 
with the lower specific surface area is better and the adhesion work of these samples is 
higher than for the samples containing the other type of magnesium stearate. 
 This experiment explains the experiences with the granules mentioned above. Also 
calls attention to the fact that the solution is not always using high specific surface area 
magnesium stearate. In case similar problems it is needed to perform this kind of 
preformulation studies. 
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5 SECTION II - FORMULATION STUDY OF MEDICATED CHEWING GUM 
AND THE EFFECT OF MAGNESIUM STEARATE 
5.1 Materials 
 During the experiments two types of commercial sourced "gum basic" was studied: 
the Pharmagum C, M, and S® named (gifts from SPI Pharma) and the Health-in-Gum® 
named (Cafosa Gum, S.A.U., Barcelona, Spain) products. Pharmagum C, M and S were used 
as gum bases. Pharmagum M has a 50% greater gum base than Pharmagum S, which consists 
primarily of gum base and sorbitol. Pharmagum M contains gum base, mannitol and isomalt. 
According to the manufacturer data, Pharmagum S is suitable for formulations with low drug 
loading and when incorporated into tablets gives them chewable character. Pharmagum M is 
suggested for medium drug loading (<50%); it improves the mouthfeel texture. Pharmagum 
C is suggested for high drug loading (>50%); it has a real chewing gum character. Based on 
the experience gained in preliminary experiments (inadequate flowability, uneven charging, 
excessive sticking - see below), mixtures were prepared using these products in different 
ratios to study the compactness and deformability (Table 19). Compactness means the 
permanent bindings which are formed during loading and deformability refers to the shape 
modification of the particles during loading. 
 In this formulation study ascorbic acid was used as model material (Ph. Eur.). Besides 
ascorbic acid as API, additional components of the mixtures were xylitol (frequently used in 
tablets as a sweetener), magnesium stearate (as a lubricant) and aroma (to give the tablets a 
better smell). 
Table 19: Compositions of powder mixtures 
 
 
 
Pharmagum 
(%) 
 
C M S 
Ascorbic 
acid 
(%) 
Xylitol 
(%) 
Aroma 
(%) 
Mg.stear. 
(%) 
S 1 60 40 - 
S 2 50 50 - 
S 3 40 60 - 
S 4 60 - 40 
S 5 50 - 50 
S 6 40 - 60 
S 7 - 60 40 
S 8 - 50 50 
S 9 - 40 60 
8.33 7.68 0.33 2.00 
API concentration: 33 mg/tablet 
Average tablet weight: 470 mg 
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 In the next formulation study the other directly compressible gum composition was 
used as matrix former (Health in Gum) (Cafosa Gum, S.A.U., Barcelona, Spain) to get a 
broader picture of the properties of these new materials (Table 20). 
Table 20: Composition of gum powders 
Component Content 
Gum base 28-32 
Sorbitol Up to 100 
Xylitol 8-12 
Plasticizer <1.5 
Antitacking agent (E-551) <2.0 
 
 Caffeine was used as API, stevioside as sweetener and in case the final investigation 
two types of magnesium stearate individually as lubricant, with different specific surface 
areas: 8-10 m2/g (Peter Greven Nederland, Venlo, The Netherlands) and 2.5 m2/g (Undesa, 
Union Derivan, S.A., Barcelona, Spain). The composition of the tablets can be seen 
in Table 21. 
Table 21: Composition of tablets 
Component Content (%) 
Caffeine 12.5 
Stevioside 2.5 
Magnesium stearate* 1.5 
Gum base powder 83.0 
API concentration: 50 mg/tablet 
Average tablet weight: 400 mg 
*Two type of magnesium stearate were used individually in the final experiments. 
All the materials used (apart from the gum base) in this product complied with their Ph. Eur. 
and USP monographs and all the components of the gum base complied with the USA Food 
and Drug Administration Code of Federal Regulations, title 21, sect. 172.615 and Food 
Chemicals Codex Specifications. 
 
5.2 Methods 
5.2.1 Preparation of mixtures 
Pharmagum based chewing gum tablets: The mixtures of two of the Pharmagum 
materials in various ratios were prepared with a Turbula mixer (Willy A Bachofen, 
Switzerland) at 50 rpm for 8 min, after which the other components were added, and mixing 
was continued for a further 2 min (Table 19). The mass of each powder mixture was 200 g. 
Cafosa based chewing gum tablets: After sieving, the components with the exception 
of magnesium stearate (Table 21) were mixed in a Turbula mixer at 50 rpm for 8 min, the 
magnesium stearate was then added, and mixing was continued for 2 minutes. The total mass 
of each powder mixture was 200 g.  
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5.2.2 Flow properties and moisture content 
 The flow properties of the gum powder were determined with a Pharma Test PTG-1 
powder rheological tester (Pharma Test Appartebau, Germany). The compaction behaviour 
of the materials was tested with an Engelsmann stampfvolumeter (J. Engelsmann A-G, 
Ludwigshafen, Germany). The moisture content of the gum powder was determined with a 
moisture analyzer (HR73 Halogen Moisture Analyzer, Mettler-Toledo GmbH, Greifensee, 
Switzerland). The standard drying program was used, with a drying temperature of 105 °C. 
The sample was heated to 105 °C and then held constant at that temperature. The powder 
was dried to constant mass.  
 Three parallel experiments were performed. 
5.2.3 Tableting 
 Two type of compression machines were used during these experiments.  
 The Pharmagum and the first Cafosa based tablets were prepared with a Korsch EK0 
eccentric tableting machine. The compression tools were flat-faced bevel-edged punches 10 
mm in diameter and equipped with strain gauges and a displacement transducer. The strain 
gauges allowed the pressure forces on the upper and lower punches to be followed with 
force-measuring equipment. The displacement transducer was fitted over the upper punch. 
The compression was carried out electrically at 36 rpm, at an air temperature of 24 °C and a 
relative air humidity of 45%. The Pharmagum tablets were compressed at compression 
forces of 5, 7.5, 10, 12.5 and 15 kN for each sample (when possible) and the Cafosa tablets 
were compressed at compression forces of approximately 5, 10, 12.5 and 15 ± 1 kN. Lots 
with relative standard deviations not exceeding 5% were accepted. The force–displacement 
curves were plotted, and the different energy/work relations were calculated from the curves 
with our own software [61].  
 Cafosa gum base containing caffeine were prepared with a Manesty eccentric 
tableting machine (BWI Manesty, Liverpool, England) and evaluated by a literature method 
[61]. The compression tools (punches) have the same geometrical parameters (diameter, 
shape) as in case Korsch EK0 compression machine. The displacement transducer was fitted 
over the upper and under the lower punch. The compression was carried out electrically at 45 
rpm, at an air temperature of 24 °C and a relative air humidity of 45%. The average mass of 
the tablets was 0.40 ± 0.02 g. 150 tablets were compressed at ~ 5 and 10 ± 1 kN. Lots with 
relative standard deviations not exceeding 5% were accepted. The force–displacement curves 
were plotted, and the different energy/work relations were calculated from the curves by 
means of F3CCA software. The measurement was repeated 10 times.  
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 All type of tablets was stored in airtight plastic containers at an air temperature of  
24 ºC and a relative air humidity of 45%. 
 The E1, E2 and E3 energies are calculated by the following equations: 
 
where 
 Fmax = maximum force during compressing; C = displacement; Fupper = maximum 
force measured on the upper punch; ds = elemental value of the displacement. The plasticity 
was calculated with the formula: Pl = E2/ E2 + E3. 
 In case when the lubricant in the formulations was not enough to avoid the sticking to 
the punches, teflon layer was used on the surface of the tools (Figure 19). 
A  B  
Figure 19: Punch without Teflon layer (A) and with Teflon layer (B) 
 
5.2.4 Friability test 
 The friability of the chewing gum tablets was tested with an Erweka TA 100 
friabilator (Erweka GmbH, Heusenstamm, Germany).  
    (3) 
 
 
    (4) 
 
 
    (5) 
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5.2.5 Deformability test 
 The deformability was tested with a modified breaking hardness tester, which was 
connected to a computer, and special owndeveloped software was applied to record the 
force–time diagram. 
 The tester contained a specimen holder and a jowl, and was connected to a computer 
via an interface. The specimen was located horizontally on a special plate and the jowl 
moved vertically. Twenty parallel measurements were performed.  
The measurement range was 0–200 N, the speed of the stamp was 20 mm/min and the output 
was 0–5 V. The sensor was a Unicell force-measuring instrument (MIKI), calibrated with the 
C9B 200 N cell. 
5.2.6 Geometrical parameters measurement 
 The height and the diameter of the tablets were measured with a digital micrometer 
(Mitutoyo, Tokyo, Japan). The measured and the calculated average values were printed out. 
Twenty tablets were measured for each sample. The average tablet volume was determined 
according to the following equation:  
pi
2
2






=
d
tV   (6) 
where t is a thickness, d is a diameter.  
 The geometrical parameters were measured at the following sampling times: directly 
after compression, and after storage times of 1, 4, 8 and 24 h and 2, 3, 4, 5, 6 and 7 days 
following tablet pressing. (In view of the large number of data, only selected data on the 
fresh tablet and the data after 1 and 7 days of storage are presented in the tables.)  
5.2.7 Surface free energy 
 The surface free energies of solid materials can be determined by means of contact 
angle measurements. The contact angles were measured on the same way as described in 
4.2.2.4 point and the calculation of surface free energy is decribed in the 3.2 point.  
 
5.2.8 Dissolution tests 
 Chewing gum tablets are intended not to be swallowed, but to be masticated in the 
mouth, where the amount of the dissolution medium (saliva) is small. The API must dissolve 
in the saliva, which is swallowed and reaches the stomach. Accordingly, the dissolution 
testers that are official in the Pharmacopoeias for conventional tablets or capsules are not 
applicable in this case. For dissolution tests there are recommendations in the Ph. Eur. [62] 
 Pharmagum based chewing gum tablets: For the dissolution tests, an Erweka 
chewing apparatus was used [52]. Each chewing gum sample was chewed with this apparatus 
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for 10, 20 or 30 min, in the presence of 20 of dissolution medium (purified water), after 
which the ascorbic acid content of the liquid was determined by spectrometry. 
 Cafosa based chewing gum tablets: However, a special apparatus for this purpose is 
described in the Ph.Eur. In the lack of this apparatus, we used a new method for the 
dissolution testing. “Chewing” was simulated in phosphate buffer (pH=7.0 ± 0.5) in a mortar 
grinder (type RM200, Retsch GmbH, Haan, Germany). 
 The chewing gum tablet was placed under the pestle and 50 ml phosphate buffer was 
poured into the mortar. The apparatus was switched on, and the pressure-induced movement 
of the pestle led to deformation of the tablet and dissolution of some of the API from the 
tablet. After various times (5, 10, 15, 20, 25 and 30 min), a 5-ml sample was taken and the 
dissolution medium was supplemented with 5 ml phosphate buffer up to 50 ml. The caffeine 
contents of the 5-ml samples were determined by spectrometrically Genesys 10S UV-Vis 
BIO, Thermo Fisher Scientific, Madison, Wi, USA, λ = 273 nm). The measurement was 
repeated 3 times. 
5.2.9 Microscopic study 
The microscopic measurements were performed on the same way as described in 
4.2.2.3 point. 
5.2.10 Porosity 
 The true density of the tablets was determined with a Quantachrome helium 
stereopycnometer (Quantachrome GmbH & Co., Odelzhausen, Germany). The measurement 
was repeated 5 times. The porosity was calculated according to the following equation: 
true
apparent
ρ
ρφ −= 1
  (7) 
5.3 Experimental results of Pharmagum chewing gum tablets 
5.3.1 Compressibility tests 
 The tests on the flow properties of the bulk gum samples showed that Pharmagum C 
and M could not flow out from either a teflon or a metal funnel, in spite of the agitation of 
the powder. Pharmagum S displayed good flowability from a teflon funnel on mixing at 25 
rpm (Table 22). The API flowed from a teflon funnel on agitation at 25 rpm. 
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Table 22: Powder rheological test 
 Material 
of the 
funnel 
Flowing 
time 
(s) 
Agitation 
speed 
(r/min) 
Angle 
of slope 
(o) 
Heap 
volume 
(ml) 
Heap 
mass 
(g) 
Ascorb. acid T 12.3 25 33.1 85.6 77.8 
Pharmagum C T/M - - - - - 
Pharmagum M T/M - - - - - 
Pharmagum S T 7.5 25 26.2 64.4 56.6 
S 1 M 12.3 10 29.3 73.4 58.8 
S 2 M 10.3 10 29.4 73.9 59.7 
S 3 M 10.0 10 29.8 75.0 58.8 
S 4 M 7.6 5 26.6 65.6 66.9 
S 5 M 7.3 10 27.5 68.2 67.8 
S 6 M 7.4 10 28.3 70.6 65.5 
S 7 M 8.3 10 29.1 73.0 66.4 
S 8 M 8.4 10 28.4 70.9 68.6 
S 9 M 8.1 10 28.1 71.5 69.3 
T = teflon; M = metal; - = not measurable 
 
 The compaction tests on the bulk materials resulted in every case in high elastic 
recovery. As concerns tablettability, the flowability and compactness can be important 
properties. Solid bridges formed during compression phase can be broken in the elastic 
recovery phase. In the tablet compositions, therefore the bulk gum powders were mixed with 
the other components in different ratios (Table 19). 
 The data in Table 22 reveal that the powder mixtures could flow from a metal funnel 
on moderate stirring. Mixture S4, which contains Pharmagum S, exhibited the best 
flowability to which an agitation speed of only 5 rpm was applied. The flowability properties 
of the mixtures containing Pharmagum S were generally better. These data are in accordance 
with the other powder rheological parameters. 
 The Carr index, calculated from the bulk and tapped densities, indicates that the 
powder mixtures have excellent compressibility (Table 23). However the mixtures adhered to 
the punches during tableting, which is an unfavorable property. Fortunately, this could be 
eliminated through the use of a teflon film on the punch surface.  
 
Table 23: Compressibility of the mixtures 
 L.d. 
g/cm3 
T.d. 
g/cm3 
C.i. 
% 
Tr.d. 
g/cm3 
S 1 0.59 0.64 8.72 7.15 
S 2 0.58 0.64 10.00 6.93 
S 3 0.59 0.64 7.95 6.85 
S 4 0.68 0.74 8.46 6.80 
S 5 0.71 0.76 5.38 6.74 
S 6 0.70 0.74 4.88 6.85 
S 7 0.70 0.73 4.61 6.69 
S 8 0.70 0.75 5.90 6.75 
S 9 0.72 0.77 6.41 6.51 
L.d.=loose density; T.d.=tapped density; Hf=Hausner’s factor; 
C.i.=Carr’s index; Tr.d.=true density 
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 The different compression parameters for the mixtures were calculated at different 
compression forces (effective work = E2, elastic recovery = E3, plasticity = Pl). For gums, 
elasticity is the most important property. After the compression maximum, when the upper 
punch starts to move upwards, elastic materials display some recovery. This phenomena only 
comes from the gum base. The elastic properties of the API and other ingredients do not have 
such high effect which causes any changes of the elastic behavior of the gum bases [63]. 
 The friability of the tablets was less than 0.1 % in all cases, and they met the 
requirements of Ph.Eur. but this is expected from a gum tablet. 
5.3.2 Chewability test 
 In the case of a chewing tablets the chewability is an important requirement. The test 
is not unique [64]. We used for this an instrumented breaking tester (5.2.5.). The chewing 
tablets differ from the conventional tablets because after crushing the tablets did not break 
completely. The deformation curves during loading demonstrate elastic deformation with a 
rather high slope (Figure 20 and 21).  
 
Figure 20: Deformation curve of a chewing tablet 
 
0
10
20
30
40
50
60
70
80
90
100
0 500 1000 1500 2000 2500
Time (ms)
Fo
rc
e
 
(N
) S4
S5
S6
 
Figure 21: Deformation curves during loading (samples S4, S5 and S6) 
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 After a maximum, the force decreased, but the tablet did not break into small pieces; 
only deformation was observed, with some cracks. Increase of the pressure did not cause any 
significant changes in the breaking process. 
 
5.3.3 Dissolution test 
 
 During the dissolution investigation the 5, 10, and 15 kN, compressed samples were 
tested. The results show that the dissolution of ascorbic acid did not depend on the 
compression force (Figure 22). In all cases, 90% of the API dissolved in the first 10 min, and 
after chewing for 30 min the whole amount had dissolved. 
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Figure 22: Dissolution profile of sample S5 
The dissolution results show that applying high compression force is not necessary during 
the manufacturing process. 
5.4 Experimental results of Cafosa chewing gum tablets 
5.4.1 Investigation of elastic recovery of tablets 
 The objective of this work was to study the elastic recovery of one of the gum base 
for direct compression at room temperature by a direct compression technique. The elastic 
recovery mentioned was examined by thickness, diameter and hardness measurement. 
 Because of the elastic recovery various phenomena can be observed after 
compression in the structure of tablets, which change the volume and the porosity. The 
driving force for the elastic recovery the bonding forces (i.e. Van der Waals forces, solid 
bridges, electrostatic forces, hydrogen bonds, etc.) and the elastic energy (stress) stored in the 
particles during densification. The stored stress can resolve and increase the tablet volume 
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and porosity. However the bonding forces which are working with the stress simultaneously 
decrease the tablet volume and porosity. The elastic recovery can be define as  
min
min
V
VV
ER t
−
=    (8) 
where Vmin is the minimum volume of the tablet under load and Vt  the volume of the tablet at 
different times t after compressing. It gives information on the remaining elasticity of the 
materials [65]. The degree of the elastic recovery depends on the property of the materials. It 
starts immadiatelly after the compression phase and is finished dependent on the material 
after several days. 
 Generally accepts the definition of tablet hardness as being the force required to break 
a tablet in a diametrical compression test. To measure the force required to break a tablet we 
obtained the tensile strength of the tablet as the following form: 
td
F
x
⋅⋅
⋅
=
pi
σ
2
    (9) 
where F is a force necessary to cause fracture, d is the diameter and t is the thickness of the 
tablet [66]. 
  
 Moisture content determination is an important preformulation test before tableting. It 
influences the flow properties of granules or powders, which must flow freely into the die 
cavity during tableting. The Hausner factor and Carr’s index are calculated from the poured 
and tapped densities of the powder. A Hausner factor of less than 1.25 (equivalent to a Carr’s 
index of 20%) indicates good flow; when it is greater than 1.5 (a Carr’s index of 33%), it 
indicates poor flow. The moisture content of the gum powder was rather low (0.3%), and the 
flowability was very good (flow time: 8.4 s). This means that the gum powder could flow 
freely in the die during the compression. The values of the Hausner factor (1.102) and Carr’s 
(Carri = 9.23%) showed that the arrangement of the particles was also good [67]. 
 It is clear from the tablet volume changes (Figure 23) that the application of higher 
compression forces imposes too much on the gum stress during storage. When the 
compression force is higher than a certain limit, the gum loses its elasticity. As noted above, 
the driving forces for the final stage of tablet formation are the bonding forces and the stress 
stored in the gum. The gum strives to release the stored stress by increasing the volume of 
the tablet, while the bonding forces decrease the volume. This phenomenon is very well 
observable at pressure force of 5, 10 and 12.5 kN (Figure 23). At 15 kN, the gum loses its 
elasticity and thus the main driving forces in the final formation stage are the bonding forces. 
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Figure 23: Volume changes of the comprimates 
 The geometrical parameters of the tablets can be seen in Table 24. The post-
compressional geometrical changes in the tablets must be taken into consideration, especially 
in blister packaging. In this case, the geometrical parameters determine the depth and 
diameter of the blister cavity. 
Table 24: Data of geometrical parameters of tablets 
Diameter*  
(mm) 
Thickness*  
(mm) Compression force (kN) 
Fresh 1 day 7 day Fresh 1 day 7 day 
5 10.030 10.010 9.997 4.242 4.217 4.206 
10 10.041 10.021 10.005 4.136 4.142 4.120 
12.5 10.044 10.027 10.013 4.155 4.139 4.135 
15 10.044 10.025 10.021 4.172 4.151 4.150 
*SD<±5% 
 It can be concluded from the data that both the diameter and the thickness of the 
tablets decreased continuously during 7 days of storage, but the degree of contraction 
differed. This is reflected in the volume changes. 
 The testing of the mechanical strength of the tablets is very important because they 
must remain intact during handling, i.e. packaging and transportation. The mechanical 
characterization of different materials and preparations is investigated in different scientific 
fields [68–70]. In our work the breaking strength of the preparation was studied. The data are 
summarized in Table 25. It can be seen that the greatest strengths were measured in every 
case at a compression force of 5 kN, and the breaking strength increased during storage. 
With increase of the compression force, the tablets exhibited lower strength and the increases 
in strength during storage were more moderate. It is noteworthy that the tablet strengths at 
12.5 and 15 kN were almost the same in every situation.  
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Table 25: Tablet strength data 
 
Breaking strength* 
(N) 
Tensile strength* 
(mPa) Compression force (kN) 
Fresh 1 day 7 day Fresh 1 day 7 day 
5 60.36 69.80 85.29 0.9036 1.0532 1.2919 
10 58.60 60.83 74.32 0.8986 0.9332 1.1484 
12.5 55.19 61.14 75.84 0.8423 0.9382 1.1667 
15 55.31 61.29 76.73 0.8408 0.9380 1.1752 
*SD<±5% 
 
 Investigation of the breaking hardness of direct compressed chewing gum tablets is 
important not only for determination of their general parameters, but also from the aspect of 
the user’s satisfaction. The preparations should provide adequate strength and ease of 
processability, and the consumer should find them pleasant and easy to use. It is not 
necessary to apply an extremely high compression force to prepare a good chewing gum 
tablets, because this will not cause any significant difference in quality wich shows great 
similarity with the previous results [63]. 
 Determination of the breaking (deformation) force (Figure 20 and 21) is important 
because it is necessary to know what energy is needed to break the chewing gum tablet. If the 
compression force is too high, the gum will not acceptable by the patient, but if it is too low, 
the tablet will not be formed during compression. 
 The breaking process, which reflects the elastic/plastic behaviour of the tablet after 
compression, occurred in accordance with the volume changes. With increase of the 
compression force, the degree of elasticity decreased (Figures 24 – 26). The action of the 
compression force can be observed very well in the case of fresh tablets (Figure 24). The 
degree of elastic recovery was highest for tablets compressed at 5 kN, but the linear section 
of the deformation curve was not too long and soft-viscous (viscoelastic) deformation 
occurred.  
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Figure 24: Breaking process of fresh tablets 
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 After storage for 1 day, the tablet compressed at 5 kN exhibited a higher elastic nature 
because the macromolecules underwent rearrangement within 1 day (Figure 25).  
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Figure 25: Breaking process of tablets after 1 day 
 The deformation profiles of the other tablets did not reveal a significant change. 
Practically no difference could be observed between the curves. Despite the increase in the 
deformation maximum of the tablet compressed at 5 kN, the shape of the deformation curves 
did not change during storage (Figure 26). 
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Figure 26: Breaking process of tablets after 7 days 
 
 
 
5.4.2 Formulation study of Cafosa-based chewing gum and its applicability as an oral 
drug delivery system 
5.4.2.1 Formulation tests 
 In the preformulation tests, the morphology of the gum base was revealed by the 
SEM photo (Figure 27) to involve irregular particles. With increasing magnification 
(Figuress 28-31), these were seen to be aggregated, formed from crystalline and 
noncrystalline smaller particles. The small crystals displayed a needle habit (Figure 30  
and 31) and the larger ones were intimate column crystals (Figure 29 and 30).  
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Figure 27: Particles of gum base (SEM)  Figure 28: Particles of gum base (SEM) 
  Magn. 100x      Magn. 200x 
 
   
Figure 29: Particle of gum base (SEM)  Figure 30: Particle of gum base (SEM) 
  Magn. 500x      Magn. 1000x 
 
 
Figure 31: Particle of gum base (SEM) 
  Magn. 2000x 
 
 Caffeine consisted of particles of different sizes and shapes (Figure 32). At higher 
magnification, small needle crystals were observed to be agglomerated in each larger particle 
(Figure 33-35). 
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Figure 32: Particles of caffeine (SEM)  Figure 33: Particles of caffeine (SEM) 
  Magn. 100x      Magn. 200x 
 
   
Figure 34: Needle crystals of caffeine  Figure 35: Needle crystals of caffeine  
  (SEM) Magn. 500x     (SEM) Magn. 1000x 
 The preformulation data relating to the surface free energy are displayed in the  
Table 26. The total free energy of caffeine was the highest, almost double that of the bulk 
Cafosa sample. The two types of magnesium stearate decreased these values a little, but there 
was basically no difference between the actions of the two magnesium stearates. The total 
free energy of the caffeine-Cafosa mixture (Cafcof) was lower than that of caffeine. It is 
interesting that the magnesium stearate with the smaller specific surface area (Cafcof-U) did 
not influence the free energy, which was similar to that for the Cafcof mixture, whereas the 
magnesium stearate with high specific surface area (Cafcof-PG) decreased the free energy to 
a higher degree. 
Table 26: Surface free energy of samples 
*gum powder, **gum powder with caffeine, 
+gum powder with magnesium stearate Undesa, ++gum powder with caffeine and magnesium  
stearate Undesa, 
‘gum powder with magnesium stearate Peter Greven, ‘’ gum powder with caffeine and magnesium stearate 
Peter Greven 
 
Caffeine Cafosa* 
gum  
Cafcof** 
 
Cafosa-U+ Cafosa-
PG’ 
Cafcof-U++ Cafcof-
PG’’ 
γtotal (mN/m) 78.15 39.00 45.59 35.50 34.25 43.94 35.01 
γD(mN/m) 42.33 32.99 34.83 29.50 29.90 30.58 27.78 
γP(mN/m) 35.82 6.02 10.75 5.61 4.34 13.35 7.23 
Polarity (%) 45.83 15.43 23.58 15.80 12.44 30.38 20.65 
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 During the preformulation compression the gum base product stuck strongly to the 
punches, and particularly the lower punch. A Teflon strip was therefore applied to the surface 
of the punches, and a lubricant (magnesium stearate) was necessary in the tablet 
composition. Two types of magnesium stearate were applied, one with a low, and one  
with a higher specific surface area. The compressional parameters of the tablets are listed in 
Table 27. 
 The data of the Table demonstrate that the elastic recovery (E3W) increased on 
increase of the compression force from ~5 kN to ~ 10 kN, but not greatly so in the case of the 
magnesium stearate with the higher specific surface area (Cafcof-PG). On the application of 
the magnesium stearate with the smaller specific surface area, E3W was much higher 
(Cafcof-U). The actions of the two types of magnesium stearate are displayed in the other 
parameters of the tablets during compression. 
Table 27: Compressional parameters of tablets 
 
Cafcof-PG 
tabl. UF (kN) LF thicknessmm) EjF (kN) Uw (Nm) Lw (Nm) Ejw (Nm) Frw (Nm) E3w (Nm) 
1 4.33 1.43 6.26 0.36 4.23 1.44 0.05 2.79 2.55 
2 4.24 1.3 6.27 0.33 2.63 1.05 0.08 1.59 1.37 
3 4.33 1.6 6.61 0.36 4.39 1.53 0.01 2.85 2.83 
4 4.44 1.5 6.2 0.33 2.37 0.8 0.03 1.57 0.95 
5 4.47 1.5 6.23 0.33 2.49 0.85 0.01 1.67 1.08 
Avg 4.36 1.48 6.31 0.34 3.22 1.14 0.04 2.09 1.76 
SD 0.094 0.142 0.17 0.018 1 0.33 0.03 0.67 0.87 
 
Cafcof-PG 
tabl. UF (kN) LF Thickness(mm) EjF (kN) Uw (Nm) Lw (Nm) Ejw (Nm) Frw (Nm) E3w (Nm) 
1 8.92 1.98 5.82 0.38 4.71 1.45 0.15 3.26 2.63 
2 9.11 1.95 5.82 0.43 4.75 1.32 0.12 3.43 2.42 
3 9.98 2.36 5.88 0.66 5.76 1.82 0.58 3.94 4.64 
4 9.77 2.7 5.81 0.61 8.9 3.7 0.55 5.2 5.42 
5 10 2.44 5.84 0.87 11.72 5.21 2.19 6.51 9.72 
Avg 9.56 2.29 5.84 0.58 7.17 2.7 0.72 4.47 4.97 
SD 0.51 0.32 0.03 1.96 3.07 1.7 0.85 1.37 2.95 
 
Cafcof-U 
tabl. UF (kN) LF Thickness(mm) EjF (kN) Uw (Nm) Lw (Nm) Ejw (Nm) Frw (Nm) E3w (Nm) 
1 4.89 1.95 6.47 1.03 24.19 13.47 4.12 10.73 21.33 
2 4.7 1.74 6.52 0.9 22.28 11.32 2.98 10.95 18.4 
3 4.78 1.74 6.23 0.9 14.01 6.17 2.61 7.84 12.68 
4 4.63 1.56 6.28 0.8 19.12 9.12 2.73 10 10.94 
5 5.28 1.8 6.49 0.92 24.62 12.85 2.62 11.76 18.74 
Avg 4.86 1.76 6.4 0.91 20.84 10.59 3.01 10.26 16.42 
SD 0.26 0.14 0.13 0.08 4.39 2.99 0.64 1.49 4.4 
 
Cafcof-U 
tabl. UF (kN) LF Thickness(mm) EjF (kN) Uw (Nm) Lw (Nm) Ejw (Nm) Frw (Nm) E3w (Nm) 
1 10.50 3.54 6.03 0.84 23.03 9.94 2.87 13.09 20.46 
2 10.10 3.28 5.88 0.85 22.72 7.02 2.59 15.70 19.14 
3 10.20 3.10 5.94 0.72 28.70 9.06 2.26 19.65 19.75 
4 9.80 3.09 6.17 0.90 28.91 11.17 2.54 17.74 23.09 
5 8.90 2.81 6.17 0.90 23.41 11.17 2.54 17.74 23.09 
Avg 9.90 3.16 6.04 0.84 25.35 9.67 2.56 16.78 21.10 
SD 0.61 0.27 0.13 0.07 3.16 1.72 0.21 2.49 1.87 
 
UF=Upper force; LF=Lower force; EjF=Ejection force; Uw=Upper work; Lw=Lower work; Ejw=Ejection work; 
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 The sticking (to the punches and to the die) mentioned on the previous page can be 
observed on the force-time and on the force-distance diagrams, reported by the software of 
Manesty compression machine. (Figure 36 and 37) 
 High difference can be seen between the the maximum pressure force of the upper 
and lower punch and the residual force is significant on the lower punch force-time diagram 
(Figure 36). Furthermore, the high degree of sticking can be observed on the force-distance 
curve of lower punch (Figure 37). 
 
 
Figure 36: Force-time diagram 
 
 
Figure 37: Force-distance/displacement diagram 
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5.4.2.2  Dissolution tests 
 Dissolution of the API from a medicated chewing gum tablet is very important. The 
results of our tests showed that the total amount of caffeine was dissolved in a short time 
(Table 28) and neither the type of the magnesium stearate nor the magnitude of the 
compression force caused any appreciable difference in the dissolution. 
 
Table 28: Dissolution of caffeine from tablets 
Cafcof tablet 
Undesa Peter Greven 
 5 kN 10 kN 5 kN 10 kN 
Time 
(min) 
Mean 
(%) 
RSD 
(%) 
Mean 
(%) 
RSD 
(%) 
Mean 
(%) 
RSD 
(%) 
Mean 
(%) 
RSD 
(%) 
71  70  68  67  5 
 1.3  2.3  0.5  2.0 
78  77  75  75  10 
 1.2  1.7  0.6  1.2 
86  86  82  82  15 
 1.6  1.7  0.2  0.5 
94  94  89  89  20 
 0.4  2.0  0.1  0.6 
100  101  96  97  25 
 1.4  2.3  0.1  1.2 
100  102  96  97  30 
 1.2  3.2  0.8  1.3 
 
 This result was rather surprising because a considerable difference in elastic recovery 
was observed between the tablets prepared with the different forms of magnesium stearate. In 
this phase the binding can break more easily, which influences the porosity of the texture.  
Table 29 reveals that neither the apparent density nor the true density of the tablets differed 
significantly and each of the tablets had the same high porosity. 
Table 29: Density and porosity of tablets 
Apparent density 
(g/cm3) 
True density 
(g/cm3) Porosity 
Type of 
magnesium 
stearate in tablet 5 kN 10 kN 5 kN 10 kN 5 kN 10 kN 
Undesa 0.1372 (s=± 0.0004) 
0.1369 
(s=±0.0013) 
0.9637 
(s=±0.0045) 
0.9591 
(s=±0.0056) 0.86 0.86 
Peter Greven 0.1365 (s=±0.0005) 
0.1359 
(s=±0.0005) 
0.9728 
(s=±0.0055) 
0.9678 
(s=±0.0047) 0.86 0.86 
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5.4.3 Evaluation of results 
 In the present work, we investigated the morphology, surface free energy and 
compactibility of Cafosa gum, a directly compressible gum composition, as a new vehicle for 
use as a drug delivery system.  
 The morphology study showed that the product consists of irregularly shaped, 
aggregated particles, formed from crystalline and noncrystalline smaller particles. The results 
of surface free energy determinations clearly indicated that Cafosa is a co-processed product 
with rather low polarity.  
 The API (caffeine) also consisted of irregular particles, SEM demonstrating small 
needle crystals agglomerated into larger particles. This morphology does not facilitate the 
flowability of the gum base, and the die was filled unevenly during compression. Magnesium 
stearate applied as an additive promoted the flowability somewhat, but not perfectly.  
 The surface free energy of caffeine and the polarity also proved to be rather high. A 
high polarity is generally very good as concerns the dissolution of an API from a tablet. 
However, the gum base and the lubricant yielded low values. There was seen to be a 
difference in the effects of the two types of magnesium stearate. In the event of higher 
surface area (Cafosa-PG) the polarity was lower. 
 As regards the compressional parameters, it was concluded that an increase of force 
increased the values, thereby worsening the compressibility and compactibility of the tablet. 
 At the same compression force, the elastic recovery and friction work were much 
higher in the case of the magnesium stearate with lower specific surface area (Cafcof-U) than 
for Cafcof-PG. The reason lies in the polarity. The Cafcof-U powder mixture was much more 
hydrophilic than that of Cafcof-PG. Since the magnesium stearate in Cafosa-PG has higher 
specific surface area, the distribution of the smaller particles between the particles of the 
tablet composition was better, ensuring improved lubrication. The distribution of the 
magnesium stearate particles with lower specific surface area was not so good, and 
unevenness and more binding could form in the die during loading, and in the elastic 
recovery phase the friction work was high because of the considerable friction between the 
side of the tablet and the die wall. It is interesting, that in contrast, the comprssion force had 
practically no influence on the ejection work. This may be explained by the elasticity, which 
may be so high at higher compression force that the tablet almost “jumps” from the die. 
 These results suggested that will differences would be observed between the tablets in 
the dissolution and the release profile. Unexpectedly, however no difference was seen 
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between the dissolution from the tablets, independently of the compression force or the type 
of magnesium stearate (Table 28).  
 As mentioned above, the elastic recovery influences the formation of the texture of 
the tablet, the binding breaks and the porosity is rather high. This is in accord with the results 
of the texture investigation. Figures 38-41 demonstrate that there is practically no difference 
in the texture of the tablets independently of the compression force and the type of lubricant. 
A matrix system can be seen in every case, with numerous pores formed inside the particles 
of the gum base, and with many narrow crevices and shattered small particles among the 
different larger particles. The sponge-like matrix can be observed especially at higher 
magnification (500x). The porosity is concordant with these observations (Table 29), which 
explains why there was no difference in dissolution rate. 
  
Magn. 200x Magn. 500x 
 
Figure 38: Breaking surface of Cafcof-U tablet  
Compression force 5 kN 
 
  
Magn. 200x Magn. 500x 
Figure 39: Breaking surface of Cafcof-U tablet  
Compression force 10 kN 
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Magn. 200x Magn. 500x 
Figure 40: Breaking surface of Cafcof-PG tablet  
Compression force 5 kN 
 
  
Magn. 200x Magn. 500x 
Figure 41: Breaking surface of Cafcof-PG tablet  
Compression force 10 kN 
 
 As concerns the fitting of the dissolution profile, it has been reported that the 
Korsmeyer-Peppas model can be used to analyze data on drug release from polymer matrix 
[71]: 
nt kt
M
M
=
∞
 (10) 
where Mt/M∞ is the fraction of drug released at time t, k is the rate constant and n is the 
release exponent. We found that the release of caffein obeyed the Korsmeyer-Peppas 
equation with a very high correlation coefficient. The results of fitting are presented  
in Table 30. 
Table 30: Dissolution parameters according to the Korsmeyer-Peppas model 
Sample k n R2 
Cafcof-U  5 kN 71.4206 0.007 0.9998 
Cafcof-U 10 kN 67.1431 0.032 0.9999 
Cafcof-PG  5 kN 70.4679 0.007 1.0000 
Cafcof-PG 10 kN 67.825 0.019 1.0000 
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6 CONCLUSIONS, PRACTICAL USEFULNESS 
Based on the introduced manufacturing problems and the measurements results 
(Section I) it is suggested to investigate during the process development what kind of 
magnesium stearate (with lower or higher surface area) is preferable to avoid the difficulties 
arising from the lubricant during further production. 
It can be stated that the manufacturing problems have been encountered when using 
the magnesium stearate with high specific surface area therefore it is suggested to start the 
composition development using the magnesium stearate with smaller specific surface area. 
It can be stated that using the correct type of magnesium stearate might helps to 
increase the similarity between the dissolution profiles of the original and the generic 
products. 
It can be concluded that the two types of magnesium stearate were distributed to 
different extents on the surface of the particles. The magnesium stearate with higher specific 
surface area was more polar with higher adhesion work, and it was able to create a very thin 
homogeneous layer on the surface of the particles. In the case of the magnesium stearate with 
lower specific surface area, enrichment was observed on the surface of the particles, 
decreasing the free energy. It is clear that the surface free energy and polarity of the materials 
influence the choice of the suitable magnesium stearate (low or high specific surface). It can 
be stated that the blending speed should not be too high because at longer mixing time the 
free energy of the other component will be dominant (see Figure 18). [72] 
Energy-dispersive X-ray fluorescence analysis was successfully used for the in-
process determination of the distribution of magnesium stearate on the surface of the 
particles. The measurement was rapid and did not require any special sample preparation. 
 The powder rheological parameters, and especially the flowability, conclude that 
Pharmagum C and M are not suitable for the preparation of direct-compressed chewing gum 
tablets. Pharmagum S increased the powder rheological properties and the compressibility, 
but all of the compositions resulted in suitable tablets at a compression force of 5 kN. The 
physical parameters and the dissolution rate from these tablets were very good, so that 
increase of the compression force was unnecessary. It can be stated that chewing gum is an 
alternative drug delivery system with several advantages especially for kids and geriatric 
patients who experience difficulties swallowing the traditional oral solid dosage forms, and it 
is possible to prepare by direct compression, which is economic preparation procedure. [63] 
 It can be concluded that the flowability of Cafosa gum powder is very good and its 
direct compression is possible. The post-compressional tests demonstrated that a 
compression force of 5 kN is sufficient for preparation. The elastic behaviour of these tablets 
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is the best from the aspect of the chewability. The advantage of these tablets is that the 
patient can chew such a tablet easily and the drug can be released in the mouth. The drug can 
then be swallowed and pass into the stomach or intestine or may be absorbed through the 
mucosa and a rapid drug effect will be obtained. [73] 
 Overall, we concluded that Cafosa gum base is a co-processed product that is 
compressible in spite of its elasticity, but during loading the tablets stick strongly to the 
punches and there is considerable friction with the die wall. The use of lubricants and 
suitable (e.g. Teflon-coated) punches therefore is necessary inon a production scale. The 
compressional parameters were better when magnesium stearate with higher specific surface 
area was used. The in vitro dissolution test employed showed that the release of caffeine in 
response to the mechanical action was rapid and quantitative and the profile obeyed the 
Korsmeyer-Peppas equation (which is valid in the case of matrix systems) very well. The 
type of magnesium stearate and the compression force applied did not influence the 
dissolution. 
 One aim of modern pharmaceutical technology is the development of different matrix 
tablets [74] with good bioavailability. The study confirmed that directly compressible gum 
may be used to prepare matrix tablets for oral transmucosal administration. 
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Régi-új gyógyszerforma, avagy a gyógyszeres rágógumi f?nix-effektusa
ifj. Kása Péter1, Jójárt Imre2, Hódi Klára1
 Bevezetés
Az ember már régóta ismeri a rágógumi élvezetét. A 
mayák már 2000 évvel ezel?tt használták a sapodilla fa 
gyantáját (chicle) fogtisztításra és a lehelet javítására. 
Ezek után a fehér gyarmatosítók terjesztették el ezt a 
szokást. Az els? rágógumi 1848-ban jelent meg a pi-
acon, az els? szabadalmat pedig 1869-ben adták ki. A 
II. Világháború után jelentek meg az els? szintetikus 
rágógumik.
Az els? hatóanyagot tartalmazó rágógumi Asper-
gum® néven 1928-ban jelent meg és még ma is kapható. 
Acetilszalicilsavat tartalmaz, melyet fájdalomcsillapí-
tásra használnak. Létezik még dimenhidrinát tartalmú 
rágógumi is, melyet utazási betegség kezelésére, meg-
el?zésére alkalmaznak. A rágógumit gyógyszerforma-
ként valójában 1978 óta ismerik el. Ekkor jelent meg az 
els? nikotin tartalmú rágógumi, melyet dohányzásról 
való leszokás segítésére alkalmaznak.
Manapság a rágógumi egyre inkább elfogadott 
gyógyszerforma. A dohányzásról leszoktatás mellett 
fontos segítséget nyújt a fogak egészségének meg?rzésé-
ben és nem hanyagolható el a szisztémás hatása sem [1].
A rágógumi története
A kutatások során kiderült, hogy a gumi rágásának 
szokása nem kizárólagosan az amerikaiaktól szárma-
zik, annak ellenére, hogy az Egyesült Államok a világ 
legnagyobb rágógumi fogyasztója. Például az ?si gö-
rögök is kedvelték a mastiche nev? gumiszer? anya-
got, melyet balzsammézga fa gyantájából nyertek. 
Dioscorides görög Þ lozófus és gyógynövényszakért? 
az 1. században írásaiban gyógyer?t tulajdonított en-
nek az anyagnak.
Mastic
A mastic (Pistacia lentiscus L.) egy 4 méter magasra 
megnöv? örökzöld cserje (2. ábra), melyet Görög-
ország Chios nev? szigetén az aromás gyantája miatt 
termesztik. Az egész mediterrán térségben, így Marok-
kóban, az Ibériai-félszigeten, Dél-Franciaországban, 
Törökországban, Szíriában és Dél-Palesztinában, s?t 
még a Kanári-szigeteken is ?shonos növénynek szá-
mít. A neve is görög eredet?, fogcsikorgatást vagy rá-
gást jelent [2]. A mastic-rágás szokása nem csak az ?si 
görögök körében volt jellemz?: a görögök és más kö-
zép-keleti népek ma is használják ezt az anyagot, méh-
viasszal keverve.
A szerz?k ismertetik a rágógumi-használat törté-
netét, majd részletesen foglalkoznak a gyógyszeres 
rágógumik kialakulásával, el?nyeivel és hátrányai-
val. Ismertetik azokat a terápiás területeket, ahol a 
gyógyszeres rágógumik használata az eddigiekhez 
képest jobb és/vagy biztonságosabb gyógyszerelés 
lehet?ségét hordozza. Bemutatják a gyógyszeres 
rágógumi el?állításának a lehet?ségeit és sorra ve-
szik azokat az eljárásokat, amelyek a gyógyszeres 
rágógumi mint gyógyszerforma vizsgálatára a ren-
delkezésünkre állnak.
1. ábra: Rágógumik 2. ábra: Pistacia lentiscus L.
TOVÁBBKÉPZ? KÖZLEMÉNYEK
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A rágógumi fejlesztésében nem sokkal jártak a görö-
gök mögött a mayák. Kutatások bizonyítják, hogy ez a 
közép-amerikai indián törzs a 2. században a sapodilla 
nev? fából nyert nedvb?l készített rágót.
Sapodilla
A sapodilla (Manilkara zapota) hosszú élet?, örökzöld 
fa, mely közép- és dél-amerikai es?erd?kben ?shonos 
(3. ábra). Akár 30-40 méter magasra is megn? és nagyon 
gyorsan növekszik. Jól ellenáll a viharoknak. A törzse 
nagy mennyiségben tartalmaz fehér gumiszer? anyagot, 
melyet „chicle”-nek neveznek. A sapodilla fák évente 
kétszer hoznak termést és egész évben virágoznak (4. 
ábra). A gyümölcs is nagy mennyiség? latexet tartalmaz.
Körülbelül 20-25 éves koruk után lehet ezeket a fákat 
„megcsapolni”. A fa kérgén halcsontváz alakú bemet-
széseket ejtenek. Körülbelül 5 kg gumi csorog ki 6 óra 
alatt. Egy fát 3-4 évente lehet megcsapolni (5. ábra) [3].
A 800-as évek környékén a maya civilizáció rejté-
lyes módon kihalt. Csak az elhagyatott templomok és 
városok maradtak fenn, valamint a rágógumi, amit a 
térségben él?k tovább alkalmaztak egészen a 19. száza-
dig.
Id?közben az amerikai telepesek újfajta rágógumit 
állítottak el? lucfeny? gyantájából. Ennek használata 
a 19. század elejéig egyre inkább elterjedt, majd ezután 
jelentek meg az els? kereskedelmi forgalomba szánt rá-
gógumik. A lucfeny?b?l készült gumit fokozatosan fel-
váltotta a parafÞ nviasz-gumi. Ahhoz viszont, hogy a 
parafÞ n gumi rágható legyen, megfelel? h?mérséklet 
és nedvességtartalom szükséges. Emiatt kés?bb más 
gumialapot kezdtek használni, azonban még ma is al-
kalmaznak édesített és ízesített parafÞ n viaszokat az 
újabb termékekben, valamint Þ nomított parafÞ n viaszt 
rágógumi adalékként.
A modern rágógumi 1869-ben jelent meg. Egy mexi-
kói vezér?rnagy, Antonio Lopez de Santa Anna fejlesz-
tette ki, aki remélte, hogy a chicle nev? anyag megfelel 
a célra. Thomas Adams feltalálót alkalmazta, hogy kí-
séretezzen az anyaggal, de ? a chicle-t nem találta meg-
felel? gumialapnak.  Azután egy napon Adams látott az 
utcán egy lányt, aki parafÞ n alapú rágógumit rágott. 
Eszébe jutott a Santa Anna kérésére vizsgált anyag. 
Újra megvizsgálta a chicle-t és úgy gondolta, hogy 
mégis ez a legmegfelel?bb rágógumi alapanyag. Egy 
helyi gyógyszerész közrem?ködését kérve lényegében 
újra felfedezték azt, amit a mayák már ezer évvel az-
el?tt használtak. Ezzel forradalmasították a rágógumi 
gyártást [4].
3. ábra: Manilkara zapota 5. ábra: Csapolás
4. ábra: Sapodilla fa gyümölcse
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Manapság a rágógumikat igen sok helyen árusítják kü-
lönböz? automatákból (6. ábra). Sajnos a legtöbb or-
szágban a rágás során ízét vesztett rágógumit egyszer?en 
csak kiköpik vagy eldobják, ami igencsak gusztustalan, 
ráadásul ráragad a cip?talpra. Ennek kiküszöbölésére az 
utcai parkolóórákhoz hasonló „használt rágógumi gy?j-
t?k” felállításával próbálkoztak (7. ábra).
A gyógyszeres rágógumik 
kialakulása, deÞ níciója
A modern gyógyszeres terápiában fontos, hogy a bete-
gek a leghatékonyabb formában jussanak a megfelel? 
gyógyszerhez. Mivel a kezelt betegek jó része a Þ atal-
korúak, illetve a gyerekek köréb?l kerül ki, igen fontos, 
hogy olyan gyógyszerformát biztosítsunk, melyet szíve-
sen alkalmaznak. Erre a célra igen megfelel? a gyógy-
szeres rágógumi. Ennek, mint gyógyszerformának – bár 
a gyógyszerkönyvek csak viszonylag kés?n vették fel a 
palettájukra – igen jelent?s múltja van:
 – 1928.: Megjelent az Aspergum®, amely az els? ható-
anyag tartalmú rágógumi. Még ma is kapható (8. 
ábra). Acetilszalicilsavat tar-
talmaz, melyet fájdalomcsil-
lapításra használnak. Ezt kö-
vet?en még dimenhidrinát 
tartalmú rágót is gyártottak, 
melyet utazási betegség keze-
lésére, megel?zésére alkal-
maztak/alkalmaznak, vala-
mint koffein tartalmú készít-
mények is készültek.
– 1978.: Megjelent az el s? niko-
tinos rágógumi, melyet dohány-
zásról leszoktatásra fejlesztettek 
ki (9. ábra). Annak ellenére, 
hogy még nem igazán elterjedt 
gyógyszerforma, ett?l kezdve 
fogadják el a rágógumit, mint 
gyógyszerhordozó rendszert.
 – 1991.: Az Európai Tanács Bizottsága a rágógumit 
önálló gyógyszerformaként ismerte el [6].
A gyógyszeres rágógumi (Masticabilia gummis 
medicata) olyan szilárd, egyadagos, f?ként gumi viv?-
anyagot tartalmazó készítmény, amelyet rágásra és 
nem lenyelésre szánnak [Ph. Hg. VIII]. A gyógyszeres 
rágógumik egy vagy több hatóanyagot tartalmaznak, 
melye(ke)t a rágás folyamán adnak le. A nyálban felol-
dott vagy diszpergálódott hatóanyag(ok) révén a rágó-
gumik szájbetegségek helyi kezelésére, vagy – amikor 
a hatóanyagok a száj nyálkahártyáján, illetve a tápcsa-
tornán keresztül felszívódnak – szisztémás kezelésre is 
alkalmazhatók [7].
A gyógyszeres rágógumi el?nyei
Hatáskifejtés
Helyi hatás
A rágógumi megfelel? gyógyszerforma a szájüreg és 
a torok gyógyszeres kezelésére. Így folyamatos ha-
tás érhet? el. Általában a rágógumi rágása több ideig 
tart, mint egy rágótablettáé, így a hatástartam is hosz-
szabb. A hagyományos rágótablettával összevetve 
a rágógumi hatóanyag-kioldódási sebessége sokkal 
kontrolláltabb, annak ellenére, hogy a rágás er?ssége 
és sebessége nagyban befolyásolhatja azt. Sok esetben 
7. ábra: Utcai, használt rágógumi gy?jt?6. ábra: Rágógumi 
adagoló készülék
I. táblázat
A rágógumi modernkori történetének fontosabb eseményei
1848.: John B. Curtis kereskedelmi forgalomba hozza az els? elkészített rágógumit „State of Maine Pure Spruce Gum”.
1850.: Curtis elkészíti az els? ízesített parafÞ n gumit.
1869. december 28.: William Finley Semple els?ként szabadalmaztatta a rágógumit (U.S patent: 98,304).
1869.: Antonio Lopez de Santa Anna megismertette Thomas Adams-al a chicle-t.
1871.: Thomas Adams szabadalmaztatta a rágógumi-készít? gépet.
1880.: John Colgan kitalálta, hogyan lehet a rágógumi ízét „meghosszabítani”.
1888.: Thomas Adams a „Tutti-Frutti” rágógumiját elkezdte automatából árusítani a New York-i metróállomásokon.
1899.: Franklin V. Canning New York-i gyógyszerész elkészítette az els? Dentyne tartalmú rágógumit.
1906.: Frank Fleer feltalálta az els? buborékot képz? rágót, melyet „Blibber-Blubber gum”-nak nevezett el.
1914.: William Wrigley, Jr. és Henry Fleer bejegyezték a „Wrigley Doublemint” márkát.
1928.: Walter Diemer a Frank H. Fleer társaság alkalmazottja elkészítette az els? színes (rózsaszín) rágógumit a „Double 
Bubble”-t [5].
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problémát jelent, hogy a rágótablettát rendszertelenül 
alkalmazzák.
Gyors szisztémás hatás
A hatóanyagok a szájnyálkahártyán keresztül, vagy a 
nyállal keveredve, abban feloldódva, a nyálat lenyelve 
a gasztrointesztinális rendszeren keresztül szívódhat-
nak fel. Mindkét esetben a vérbe kerülve szisztémás 
hatás érhet? el.
Kevesebb mellékhatás
A szájnyálkahártyán felszívódó hatóanyagok a májat 
elkerülve jutnak a szisztémás keringésbe. Így nincs 
„Þ rst pass effect”, tehát nagyobb a hatóanyag biológi-
ai hasznosíthatósága. Ebb?l következik, hogy kisebb 
mennyiség? hatóanyagra van szükség a megfelel? ha-
tás kifejtésére. Az alacsonyabb dózis pedig kevesebb 
mellékhatást okoz, ennek megfelel?en csökken az 
adott hatóanyag alkalmazásának kockázata.
A túladagolás kisebb veszélye
Rágás szükséges ahhoz, hogy a hatóanyag kioldódjon 
a rágógumiból. Ha a rágógumi véletlenül lenyelésre 
kerül, a hatóanyag csak hosszú id? után oldódik ki. Ez 
nem hordozza magában a túladagolás veszélyét.
Egyéb el?nyök
Normális esetben a gumi nem jut le a gyomorba, így 
a gasztrointesztinális traktusba nem kerül segédanyag. 
A gyomor nem érintkezik közvetlenül nagy koncent-
rációjú hatóanyaggal (nyálkahártya védelem). A ható-
anyag hatása hosszabb ideig tart. Az acetilszalicilsav, 
a dimenhidrinát és a koffein gyorsabb felszívódást mu-
tat, mint tablettákból.
Komfortosság
Elfogadottság a gyerekek körében
Sok gyereknek nehézséget jelent a tabletta lenyelése. 
Emiatt a folyékony gyógyszerformák fejlesztését szor-
galmazzák, annak ellenére, hogy köztudottan ezeknek 
a gyógyszerformáknak az adagolása nem kell? pon-
tosságú. Rágógumi formában gyakran egyszer?bb a 
hatóanyag keser? és rossz ízét elfedni. Ez a gyerekek 
szempontjából el?nyös, viszont fontos, hogy a gyere-
kek az el?írt ideig rágják a rágót. 
Elfogadottság a nyelési problémákkal szenved?k körében
A nyelési problémákkal küzd?k kezelésében a rágógu-
mi el?nyös gyógyszerforma. Emellett hányinger esetén 
is jobban tolerálható, mint a tabletta.
Felhasználóbarát
A bevételéhez nincs szükség vízre, ezért akut kezelésre 
megfelel. A gyógykezelés nincs helyhez és id?höz köt-
ve, alkalmazása „komfortos” [8].
A rágógumik hátrányai
A szorbit tartalmú rágógumik hasmenést, illetve gáz-
fejl?dést okozhatnak, abból adódóan, hogy megemel-
kedik az ozmotikus nyomás a gasztrointesztinális 
traktusban. Az ízesítéshez alkalmazott segédanyagok 
fekélyt (pl. fahéj) vagy magas vérnyomást (pl. édes-
gyökér) okozhatnak. A klórhexidin tartalmú rágógumi 
kellemetlen íz?, rövid ideig használható. Különböz? 
mértékben odaragadhat a fogakhoz, fogtömésekhez. 
Hosszú idej? rágás fájdalmat okozhat az arcizmokban 
és a rágóizmok görcsét okozhatja [6].
Alkalmazási lehet?ségek
Fogszuvasodás kezelése
A fogszuvasodás kezelésére és megel?zésére kézenfekv? 
a rágógumi, mint gyógyszerforma. A cukormentes rágó-
8. ábra: Narancs íz? acetilszalicilsav tartalmú rágógumi
9. ábra: Nikotin tartalmú rágógumi
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gumik rágása köztudottan el?nyös 
a fogak egészségének meg?rzése 
érdekében. Ismert, hogy a húsételek 
fogyasztása után a cukormentes rá-
gógumi rágása újra megemeli a száj 
pH-értékét. Az alacsony pH nagy 
szerepet játszik a fogszuvasodás 
kialakulásában. Ennek megfelel?en 
az étkezések után a cukormentes rá-
gógumi alkalmazása kiegészít? ke-
zelése lehet a fogszuvasodás meg-
el?zésének a fogmosás mellett.
A klórhexidin tartalmú rágógu-
mi alkalmazása csökkenti a 
gingivitis, periodontitis és egyéb 
szájüregi fert?zések kialakulását, 
valamint csökkenti azok tüneteit. 
Bizonyított, hogy a klórhexidin gátolja a lepedékképz?-
dést, emellett gátolja a fogak elszínez?dését, rágógumi-
ként pedig kényelmesebben alkalmazható, mint szájvíz 
formájában. Rágás során egyenletesen szabadul fel a 
hatóanyag és egyenletesen eloszlik a szájüregben, ezál-
tal megnyúlik a hatástartam. A ß uorid tartalmú rágógu-
mit gyerekeknél olyan területeken alkalmazzák, ahol az 
ivóvíz nem tartalmaz elegend? ß uoridot, feln?tteknél 
pedig, ha fokozott a fogszuvasodás kialakulásának ve-
szélye. Xerostomiás betegek kezelésére is alkalmaznak 
ß uorid tartalmú rágógumit. A gombaellenes mikonazolt 
candidiasis kezelésére alkalmazzák. Rágógumi formá-
jában sokkal hatásosabb, mint orális gélben eloszlatva. 
Emellett a betegek jobban kedvelik a kevesebb mellék-
hatás miatt.
Dohányzásról leszoktatás
Klinikai vizsgálatok alapján a nikotin, lobelin és ezüst-
acetát tartalmú rágógumik segíthetnek leszokni a dohány-
zásról. A nikotin alkalmazása segít a dohányosoknak ab-
ban, hogy a cigarettázás abbahagyása után könnyebben 
„átvészeljék” az elvonási tüneteket. Egy farmakokinetikai 
tanulmány rámutatott, hogy a rágógumiból felszabadult 
nikotin 80%-a a szájnyálkahártyán keresztül szívódik fel.
Elhízás
Számos rágógumi-összetétel tartalmaz koffeint, gua-
ranát vagy krómot. A koffein és a guarana fokozza a 
lipolízist, fokozza a teljesít?képességet és csökkenti az 
éhségérzetet. A króm javítja a vércukorszintet. Ez alap-
ján ilyen hatóanyag tartalmú rágógumi alkalmazásával 
csökkenthet? a testtömeg.
Fájdalomcsillapítás
A már korábban említett Aspergum® volt az els? ható-
anyag tartalmú rágógumi, melyet fájdalomcsillapításra 
alkalmaztak. A fájdalomcsillapítás mellett lázcsillapító 
hatással is rendelkezik, valamint gátolja a trombocita-
aggregációt és így lassítja a véralvadást. Vizsgálták az 
acetilszalicilsav biológiai hasznosíthatóságát tabletta 
és rágógumi formájában is. A felszívódás sebessége a 
rágógumiból gyorsabbnak bizonyult, mint tablettából. 
Ennek megfelel?en az acetilszalicilsav tartalmú rágó-
gumi gyorsabban fejti ki a hatását, mint a tabletta, így 
gyorsabban csökkenthet? a fájdalom. A rágógumi emi-
att sokkal alkalmasabb akut, er?s fájdalom kezelésére. 
Metadon hatóanyag esetén a tabletta és rágógumi 
között a felszívódásban nem volt szigniÞ káns különb-
ség. Azonban a hozzászokás/visszaélés/túlzott bevitel 
esélye jelent?sen csökkenthet?, ha a hatóanyagot rágó-
gumi formában alkalmazzuk, mert a hatóanyag csak 
rágás hatására szabadul fel.
Utazási betegség
A rágógumi, mint gyógyszerhordozó rendszer ideális 
az utazási betegség és a hányinger kezelésére, megel?-
zésére. A dimenhidrinát tartalmú rágógumi már forga-
lomban van, de egyéb hasonló indikációjú hatóanya-
gok (pl. szkopolamin, metoklopramid, ondanszetron 
és dolaszetron) ilyen formájú alkalmazása még „várat 
magára” [6].
Allergia kezelése
Az iparosodott országokban a gyerekek kb. 20%-a 
szenved valamilyen allergiás megbetegedésben. A 
legjellemz?bb tünetek az eldugult orr vagy orrfo-
lyás, a tüsszögés, a szemviszketés, esetleg szájvisz-
ketés. A gyermekek a tünetek miatt gyakran nyug-
talanul alszanak, csökkent koncentrálóképesség?ek, 
nehezen hallanak, csökkent étvágyúak és lassabban 
fejl?dnek. Az allergiás rhinitis kezelésére használt 
hatóanyagok, melyeket rágógumi formájában is al-
kalmaznak: antihisztaminok, dekongesztánsok, anti-
leukotriének.
10. ábra: A gyógyszeres rágógumi a képregényekben
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ADHD kezelése
Az ADHD (Attention DeÞ cit Hyperactivity Disorder) 
Þ gyelemhiánnyal vagy hiperaktivitással járó kórforma. 
Egy USA-ban végzett felmérés alapján az iskolaévek 
alatt a gyermekek 5-10%-a szenved ebben a beteg-
ségben. Jellemz? tünetek: tanulási nehézségek, zavart 
viselkedés, barátkozási nehézségek, rongálási hajlam. 
Az ezekben az esetekben használt gyógyszerekben a 
következ? hatóanyagokat alkalmazták: metilfenidát, 
amfetamin, dextroamfetamin, pemolin, atomoxetin. 
Irodalmi adatok vannak arra vonatkozóan is, hogy a 
hatóanyag tartalmú rágógumi alkalmazása ennél a be-
tegségcsoportnál is hatásos lehet [9].
El?állítási lehet?ségek
A rágógumi el?állítása során a hagyományos (olvasz-
tásos) módszert, az extrudálást és a közvetlen tablettá-
zást lehet használni.
Hagyományos el?állítás
A rágógumi-gyártásnál használnak gumialapot és ada-
lékokat (pl. kukoricaszirup, glukóz, porcukor, lágyító 
és ízesít?anyagok). Ezen anyagoknak szigorú min?sé-
gi követelményeknek kell megfelelniük. A legtöbb rá-
gógumit hasonló gyártásmenet szerint készítik. Habár 
rendelkezésre állnak a rágógumi-gyártáshoz a termé-
szetes anyagok, a növekv? igények miatt szükség van 
mesterséges anyagok alkalmazására is. A gumialapot 
egy nagy, kb. 150 °C h?mérséklet? g?zfürd?s üstben 
olvasztják meg [10] (11. ábra). Így szirupszer? anya-
got nyernek. Ezután ezt a szirupot többféle lyuknagy-
ságú sz?r?n sz?rik át. Ez alatt az olvadék végig forró 
marad. Ezután az anyag kever? medencékbe kerül, 
amelyekben lassan forgó lapátok vannak felszerelve. 
A kukoricaszirupot és a cukrot a gyártási folyamatnak 
ebben a szakaszában adják hozzá. Az adalékok – pél-
dául a porcukor – meghatározzák a gumi tördelhet?-
ségét, rugalmasságát. Az adalékanyagok megtartják a 
nedvességet és segítik a cukor elegyedését a gumialap-
pal. Ezután adják hozzá a különböz? lágyító és ízesít? 
anyagokat.
A kikevert gumi h?t?szalagokra kerül és hideg leveg?-
vel h?tik. Ezután préselik, hogy megfelel?en lágy és sima 
állományú legyen. Ezt követ?en ellapítják az anyagot erre 
szolgáló gépekkel. Itt nyeri el a rágógumi a végleges vas-
tagságát (12. ábra). A különböz? vastagságúakból külön-
böz? rágótípusok gyárthatók: a legvékonyabból a lapkará-
gó, vastagabból a bevonatos rágó, a legvastagabból a 
„bubble gum” készül. Ezeket különböz? gépekkel for-
mázzák. A rágógumikat a formázási m?veletek elvégzése 
után, ha kell, különféle bevonatokkal látják el [4].
Extrudálás
Extrudálás esetén a feldolgozni kívánt anyagot egy 
arra alkalmas berendezés segítségével többé-kevésbé 
vékony szállá vagy rúddá formálják (13. ábra), amit 
egy megfelel? daraboló berendezéssel egyforma dara-
bokra vágnak, majd kialakítják a végleges formát. Ez 
az esetek nagy többségében gömb alak, amit speciá-
lis hengerekkel vagy hengerekben érnek el. A kapott 
terméket kés?bb különböz? szín? és íz? bevonattal is 
elláthatják. A m?velet során fontos a megfelel? h?mér-
11. ábra: A rágógumi- gyártás menete
12. ábra: Rágógumi gyártása manufakturális módon
A B C D
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séklet megválasztása, amivel az anyagot olyan állapot-
ba hozhatják, hogy az „szállá” alakítható. A szálak ki-
alakítása a berendezés dobja körül lév? f?t?szálak se-
gítségével folyik. A dob körül kialakított f?t?-, illetve 
adott esetben h?t?köpeny segítségével a termék szá-
mára legkedvez?bb h?mérséklettartomány állítható be.
Közvetlen tablettázás
A rohamos fejl?dés miatt, valamint az egyre nagyobb 
igények kielégítése és egyúttal a költségek csökkenté-
se érdekében a közvetlen tablettázás is el?térbe került 
a rágógumik el?állítása során. Ma már rendelkezésre 
állnak olyan gumialapok, amelyek szilárd formában 
(por) hozzáférhet?k, s megfelel? arányban kombinál-
va, a különböz? segéd- és hatóanyagot/hatóanyagokat 
hozzáadva és homogenizálva direkt préseléssel is ki-
alakítható a végleges alak. Tartalmazhatnak pl. töl-
t?anyagokat, lágyítókat, édesít?szereket, ízjavítókat, 
stabilizátorokat, képlékenységet növel? anyagokat, 
továbbá engedélyezett színezékeket. Ebben az eset-
ben inkább rágógumi tablettáról kell beszéljünk, 
hiszen a kialakított forma inkább tablettához hason-
lít! A tablettázógéppel történ? kialakítás során az 
extrudálással szemben nem f?tést, hanem h?tést kell 
alkalmazni az anyag megfelel? reológiai tulajdon-
ságainak megtartása érdekében. Ügyelni kell arra, 
hogy a préselni kívánt anyag az összepréselés után 
lehet?leg ne ragadjon a présszerszámokhoz. A raga-
dás a présszerszámok felületén kialakított speciális 
bevonattal nagymértékben lecsökkenthet?. Problémát 
okozhat, ha az így el?állított termék túlságosan szi-
lárd, hiszen össze kell rágni!
A gyógyszeres rágógumik vizsgálata
Kioldódás vizsgálat
A gyógyszerkönyv a gyógyszeres rágógumikra különbö-
z? vizsgálatokat ír el?. Ezek közé tartozik a hatóanyag 
kioldódásának vizsgálata [7]. Ehhez egy speciális rágó-
cellát ír el?, amelyben a vizsgálni kívánt terméket, külön-
böz? rágóidomok segítségével adott ideig „rágatja”, majd 
az id? függvényében kioldódott hatóanyagot megfelel? 
analitikai módszerekkel határoztatja meg (14. ábra).
A gyógyszerkönyvi rágást szimuláló készülék (14. 
ábra A.) egy kb. 40 ml-es „rágókamrából” áll, amely-
ben a rágógumit két, vízszintes irányba mozgó dugaty-
tyú mesterségesen rágja. A dugattyúk állandó sebes-
séggel, összehangoltan m?ködnek, képesek a saját ten-
gelyük körül, egymással ellentétes irányban forogni és 
ily módon er?s rágást szimulálni. Egy harmadik (füg-
g?leges) dugattyú (a „nyelv”) a két vízszintes dugattyú-
val váltakozva m?ködik és biztosítja, hogy a rágógumi 
a két vízszintes dugattyú között, a megfelel? helyen 
maradjon. A dugattyúkat s?rített leveg? mozgatja, egy-
máshoz viszonyított mozgásuk szabályozott. A készü-
lék minden eleme rozsdamentes acélból készül.
Beállítható a vizsgáló közeg h?mérséklete (37 ± 0,5 
°C) és a dugattyúk sebessége. Általában 20 ml, pH 6 
körüli tompítóoldatban történik a vizsgálat. A vizsgála-
tot üres berendezéssel kezdik, ellen?rizend?, hogy nem 
maradt-e az el?z? vizsgálatból bármiféle maradék a 
rendszerben, majd pontosan mért rágógumit helyeznek 
a cellába. Megadott id?közönként mintát vesznek és 
meghatározzák a kioldódott hatóanyag mennyiséget. A 
szokásos rágófrekvencia percenként 60 rágóciklus. 
Az Erweka által kifejlesztett rágócella (14. ábra B.) 
némileg eltér a gyógyszerkönyvben szerepl?t?l. Ebben 
a cellában egy mozgó dugattyú található, amely vertiká-
lis irányban és a saját tengelye körül is mozog. A tengely 
körüli elfordulás mértéke, valamint a függ?leges irányú 
elmozdulás – ami a rágás er?sségét imitálja – szabá-
lyozható. A dugattyút ebben a készülékben is s?rített 
leveg?vel mozgatják. A készülék kb. 20-30 ml vizsgáló-
közeget tartalmaz egy temperálható tartályban. A min-
tát a rágóidom részben összenyomja, részben pedig meg 
is csavarja, mintegy imitálva a természetes rágási folya-
matot. A pontosan mért mintát a kett?s falú cellába he-
lyezik. Adott id?közönként itt is mintát vesznek a kiol-
dóközegb?l, s a kioldódott hatóanyagot határozzák meg.
Rághatósági vizsgálat
Az el?állítási eljárástól függ?en egyéb vizsgálatokat (pl. 
szilárdságvizsgálatot) is kell végezni. Erre a célra a tab-
letták vizsgálatához el?írt szilárdságvizsgáló berende-
14. ábra: A Gyógyszerkönyvben hivatalos (A) és az Erweka 
cég által kifejlesztett (B) rágógumi vizsgáló készülék
13. ábra: Extrudáló sematikus ábrája
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zést használják. Szükséges ugyanis, hogy az elkészített 
termékek rághatóak legyenek, azaz ne kelljen túl nagy 
er? a szétrágásukhoz.
Elaszticitás vizsgálat
A rágógumik tulajdonságuknál fogva több-kevesebb 
rugalmassággal is rendelkeznek, amelyet az összeté-
telben szerepl? anyagok aránya is nagymértékben be-
folyásol. Ennek vizsgálata speciális interface és prog-
ram segítségével, valamint számítógéppel összekötött 
készülékkel történhet. A 15. ábrán egy hagyományos 
tabletta törési folyamata, a 16. és 17. ábrán a frissen 
készített, valamint a 3 hónapig tárolt gyógyszeres rá-
gógumi törési folyamata látható. Az ábrákon igen 
szembet?n?k a különbségek. A 15. ábrán a hagyomá-
nyos tabletta esetében a maximális törési er? elérése 
után az er? értéke gyakorlatilag azonnal nullára esik, 
ami azt mutatja, hogy a tabletta teljesen eltört. A 16. 
és 17. ábrán a maximális törési er? elérése után az er? 
értéke nem esik nullára, ami azt mutatja, hogy a készü-
lékbe helyezett minta nem került ki a nyomóidom alól, 
csak „megroggyan”, nem esik két részre, hanem az 
összetételben szerepl? anyagok összetartják a darabo-
kat, amelyek a nyomás hatására távolodnak egymástól. 
A 17. ábrán a tárolás következtében fellép? utókemé-
nyedés is megÞ gyelhet?.
Csomagolás
A gyógyszeres rágógumik gyártása, csomagolása, tá-
rolása és forgalmazása folyamán megfelel? intézke-
désekkel biztosítani kell a mikrobiológiai tisztaságot 
[7]. Ezen készítményeket a tablettákhoz hasonlóan 
bliszterezhetik, m?anyag dobozba tehetik vagy egyen-
ként csomagolhatják. Minden esetben fontos annak 
biztosítása, hogy a termék a leveg?t?l, a nedvességt?l 
megfelel?en elzárva legyen.
Összefoglalás
A szilárd gyógyszerformák, valamint az ezekben al-
kalmazott segédanyagok fejl?dése lehet?vé tette, hogy 
egy régi-új forma, a gyógyszeres rágógumi ismét el?-
térbe kerülhessen. Az ebben a gyógyszerformában 
használatos alapanyagok feldolgozhatósága nagy-
mértékben egyszer?södött, s a korábbiakkal szem-
ben biztosítják az egyenletes hatóanyag-eloszlást és a 
megfelel? hatóanyag-felszabadulást. Újabb lehet?ség 
a gyógyszeres rágógumik tablettázógéppel történ? el?-
állítása, mely jelent?s költség- és id?csökkent? ténye-
z?, hiszen az anyagok homogenizálása után azonnal 
tablettázható. Természetesen ezen termékek esetében 
is megfelel? vizsgálatokkal kell meggy?z?dni az el?ál-
lított „rágógumi-tabletták” min?ségér?l. Mivel a ható-
anyagmentes rágógumi világszerte igen nagy mennyi-
ségben eladott termék, feltételezhet?, hogy a betegek 
kedvez?en fogadják, hiszen bizonyos tekintetben (nem 
kell lenyelni, nem kell víz hozzá) sokkal egyszer?bb és 
kényelmesebb az alkalmazása, mint a klasszikus tab-
lettának. Világszerte egyre többféle hatóanyagot pró-
bálnak ebben a gyógyszerformában feldolgozni, ezzel 
is szélesítve a gyógyszerforma palettát. Ily módon ez 
a sokáig elfeledett gyógyszerforma ismét bekerülve a 
gyógyszerkönyvekbe, mint a f?nixmadár, újra éledve 
kerülhet el?.
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Chewing gum as a drug delivery system, Ellermann 
Carecom International, Copenhagen. 2. kiad. p. 2. 2003. 
– 2. http://www.fertin.com/Þ leadmin/pdf/Chew ing_gum_
15. ábra: Hagyományos tabletta törési folyamata
16. ábra: Gyógyszeres rágógumi törési folyamata
17. ábra: Tárolt (3 hónap) gyógyszeres rágógumi 
törési folyamata
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Study of the behaviour of magnesium stearate with different speciﬁc
surface areas on the surface of particles during mixing
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The behaviour of two types of magnesium stearate with different speciﬁc surface areas on
granule particles was examined. The magnesium stearate concentration was measured with
an energy-dispersive X-ray ﬂuorescence analyser. Different measurement procedures were
used to investigate the properties of the two types of magnesium stearate when using dif-
ferent blending times and rotation speeds. Correlations were found between the speciﬁc
surface area of the magnesium stearate, the blending time, the rotation speed and the spe-
ciﬁc surface free energy of the excipients. If magnesium stearate has a high speciﬁc surface
area it shows higher adhesion work and is able to create a very thin homogeneous layer
on the surface of the particles. Magnesium concentration was detected with the energy-
dispersive X-ray ﬂuorescence analyser. Based on the X-ray investigation the optimum
blending time and rotation speed can be determined.
Keywords: magnesium stearate; speciﬁc surface; spreading; X-ray analysis; surface energy
1. Introduction
Solid dosage forms such as tablets and capsules are the most popular drug delivery systems.
Tablet and capsule dosage forms mainly contain active pharmaceutical ingredients and excipi-
ents [1]. The excipients may be diluents, binders, disintegrants, glidants and lubricants; lubri-
cants are usually added in the ﬁnal stages of mixing of the formulation components, prior to
compression or encapsulation. Both tablets and capsules require lubricants in their formula-
tions in order to reduce the friction between the powder and metal surfaces. The main func-
tion of the lubricants is to prevent the adhesion of compacts to the surface of the punches,
dyes or encapsulating tools used in pharmaceutical manufacture [2,3].
Magnesium stearate is the lubricant most widely used during tablet compaction and cap-
sule ﬁlling operations in the pharmaceutical industry. It is preferred because of its low cost,
its high lubrication potential, its high melting point and its chemical stability. It is well known
that magnesium stearate acts as a lubricant by forming a semi-continuous ﬁlm on larger
excipient particles due to its very small particle size [4–6]. As with other salts of fatty acids,
its activity is believed to derive from the adhesion of the polar metal portion of the molecule
to the powder/granule particle surface. As a consequence, the non-polar hydrocarbon moiety
of the molecule is oriented away from the surface [7] towards the adjacent powder/granules
particles and structures such as the press or encapsulate tooling. The advantages and
*Corresponding author. Email: p.kasa@pharm.u-szeged.hu
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disadvantages of the use of magnesium stearate in tablets or capsules arise from the behaviour
of this non-polar layer. For example, its hydrophobic nature often retards liquid penetration
into the capsule ingredients, so that a capsule-shaped plug often remains after the shell has
dissolved in the gastrointestinal ﬂuids, especially when the contents have been machine-ﬁlled
as a consolidated plug [2].
The lubrication effect is inﬂuenced by the mixing time and speed, the speciﬁc surface area
and the spreading coefﬁcient of the magnesium stearate. The spreading coefﬁcient can be calcu-
lated via the free surface energy [8,9], which is widely assessed indirectly from wettability mea-
surements [10–12]. In the method of Wu and Brzozowski, the surface free energy is taken as the
sum of the dispersive and the polar components. The surface free energies of solid materials can
be determined by means of contact angle measurements, using two liquids with known polari-
ties, which involve the solution of an equation with two unknowns (Equation (1)) [13]:
ð1þ cosÞcl ¼
4ðcds c
d
l Þ
cds þ c
d
l
þ
4ðcpsc
p
l Þ
c
p
s þ c
p
l
ð1Þ
where Θ is the contact angle, γs is the solid surface free energy, and γl is the liquid surface
tension. If the surface free energies of the solid materials are known, the spreading coefﬁcient
(S) can be computed and the interactions between the two materials can be predicted. S is cal-
culated as the difference between the adhesion work and the cohesion work. The two materi-
als that interact can be two powders, a powder and a liquid (e.g. a core and a layering ﬂuid),
or any material and an equipment.
The spreading coefﬁcient (S12) of one material (1) over the surface of another material (2)
can be determined according to the following equation (Equation (2)) [14]:
S12 ¼ 4
c
d
1c
d
2
c
d
1 þ c
d
2
þ
c
p
1c
p
2
c
p
1 þ c
p
2
#
c1
2
 
ð2Þ
The spreading coefﬁcient shows how one of the substances extends over the other one. If this
is a positive number, then the examined substance spreading is preferred. The higher the
number, the greater the spreading. If this number is small or negative it means that the mate-
rial cannot stretch out on the granules of the other substance. So, if the spreading of the lay-
ering material on the surface of the core is insufﬁcient, the efﬁciency of layering and the
properties of the layer formed may be restricted.
The aim of the present study was to test the effects of various parameters on the distribu-
tion of magnesium stearate on the surface of particles in the mixtures.
A compact table-top energy-dispersive X-ray ﬂuorimeter was used for the elemental anal-
ysis of magnesium. This technique is suitable for the direct measurement in drugs of the ele-
ments ranging from sodium to uranium [5,15].
When a material is irradiated by the beam from an X-ray tube, its constituent atoms are
excited. This causes them to emit X-ray ﬂuorescence. Each element in the sample emits its
own uniquely characteristic ﬂuorescent radiation, with an intensity directly related to the con-
centration of that element in the material. This phenomenon is the basis of X-ray ﬂuorescence
spectrometry. The ﬂuorescence comprises discrete X-ray photons emitted at various (charac-
teristic) energy levels. Photons of all energies are received simultaneously by the detector of
the spectrometer and converted into a series of electrical signals, which are electronically
ampliﬁed, processed and transformed into digital values. The digital values are stored in a
multichannel analyser, which separates them according to the energy levels of the photon.
The result is the spectrum for the sample, which is further processed by the software to deli-
ver a result calculated directly in terms of element concentrations [16].
2 I. Jójárt et al.
D
o
w
n
lo
ad
ed
 b
y
 [
P
et
er
 K
ás
a]
 a
t 
0
8
:3
9
 0
5
 S
ep
te
m
b
er
 2
0
1
2
 
2. Materials and methods
2.1. Materials
Two types of magnesium stearate were used as lubricants, with different speciﬁc surface
areas: 8–10m2/g (Peter Greven Nederland, Venlo, the Netherlands) and 2.5m2/g (Undesa,
Union Derivan, S.A., Barcelona, Spain)
The other materials applied were levodopa (TEVA PFC S.R.L., Italy) (3) and benserazide
hydrochloride (CHEMI S. p. A., Italy) (4) (Ph.Eur.) and granule containing both the active
ingredients.
2.2. Methods
2.2.1. Blending
The granules were mixed separately with 1 w/w% of the two types of magnesium stearate in
a Turbula mixer (W.A. Bachofen Maschinenfabrik, Switzerland). The two mixtures were
blended in two ways to prepare samples for examinations:
(a) at a ﬁxed blending speed of 25 rpm for various times (2, 5, 8, 10 and 15min), and
(b) at various blending speeds (25, 50, 75 and 90 rpm) for a ﬁxed time of 5min.
2.2.2. X-ray ﬂuorescence analysis
Measurements on the samples were made with a Philips MiniPal PW 4025 (MiniPal, Philips
Analytical, Almelo, the Netherlands) energy dispersive X-ray ﬂuorescence analyser. During
the measurements, the conditions applied were 4 kV, 1000A and 1 bar He purge. The samples
were measured for 600 s, and the measurements were repeated in triplicate for each sample.
The concentration of magnesium was calculated by means of linear calibration (r2= 0.9980)
from the intensities of the K lines of the detected radiation. The K value of magnesium occurs
at 1.253 keV (Figure 1).
2.2.3. Morphological study
The surfaces of the samples were tested with a scanning electron microscope (SEM) (Hitachi
S4700, Hitachi Scientiﬁc Instruments Ltd., Tokyo, Japan). A sputter coating unit (Polaron
E5100, VG Microtech, UK) with gold cathode was used to charge the surfaces for the SEM
measurements. The air pressure during the analyses was 1.3–13mPa.
Journal of Adhesion Science and Technology 3
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2.2.4. Measurement of contact angle
Contact angles were measured on ﬂat comprimates 12mm in diameter and 4mm in height,
compressed with a hydraulic press (Röltgen GmbH & Company KG, Sollingen, Germany) at
1MPa from the bulk materials (levodopa, benserazide hydrochloride, granules and magne-
sium stearate).
An automatic syringe was used for the dropping, and circle ﬁtting was applied to deter-
mine the contact angles formed on comprimates prepared from different samples. The test ﬂu-
ids were distilled water and diiodomethane (Merck KGaA, Darmstadt, Germany). In the case
of water, the drop volume was 10 μl (hydrophilic liquid), while in the case of diiodomethane
(hydrophobic liquid), it was 3 μl. The advancing contact angles were measured. In the case of
water the drop age was 5 s, and in the case of diiodomethane, it was 2 s. According to Ström
[17], the dispersion component of the surface tension is 21.8mN/m for water and 50.8mN/m
for diiodomethane, while the polar component of the surface tension is 51.0mN/m for water
and 0.0mN/m for diiodomethane.
3. Results and discussion
The SEM micrographs showed that the magnesium stearate with higher speciﬁc surface area
(Figure 2) was evenly distributed over the granule surface, while the magnesium stearate with
lower speciﬁc surface area (Figure 3) exhibited enrichment on the surface of the particles.
The difference in grain size between the two types of magnesium stearate was clearly visible.
The samples were examined by X-ray ﬂuorimeter. At constant blending speed, with varia-
tion of the duration of blending, magnesium concentration was the highest at the duration of
8min (Figure 4) for both types pf magnesium stearate. This phenomenon demonstrates that
the covering of the particles by magnesium stearate is the highest at this time. After a longer
mixing time, an overmixing can be observed.
Additionally, it was seen that the magnesium stearate with lower speciﬁc surface area
resulted in higher magnesium concentrations. This is in accordance with the visual observa-
tions (Figures 2 and 3) that the particles containing magnesium stearate with higher speciﬁc
surface area formed a thinner, but uniform layer.
Figure 1. Energy dispersive spectrum of Mg.
4 I. Jójárt et al.
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When the blending was performed for a ﬁxed period of time at different blending speeds,
it was found that the highest magnesium content was measured at 25 rpm for both forms of
magnesium stearate (Figure 5), with higher speeds again leading to overmixing. The magne-
sium stearate layer was thinner, but further increase in the speed did not cause any change in
the homogeneity for the 5-min blending.
The lubrication effect of magnesium stearate depends on its spreading ability on the sur-
face of the particles. The spreading coefﬁcient can be calculated from the wetting contact
angles. From these data, it is possible to calculate the total surface free energy, its polar and
dispersive parts, and the adhesion work. The data are presented in Table 1.
It can be seen from the data that levodopa and benserazide have high surface free energies
and their characteristics strongly inﬂuence the surface properties of the granules (Table 1,
Figure 3. Distribution of magnesium stearate with the lower speciﬁc surface area (Undesa) on the
surface of the granules.
Figure 2. Distribution of magnesium stearate with the higher speciﬁc surface area (Peter Greven) on
the surface of the granules.
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SE2). Both types of magnesium stearate have much lower surface free energies, but it is note-
worthy that for the magnesium stearate with higher speciﬁc surface area, the polar part is
zero, and the apolar nature therefore dominates. This affects the value of the spreading
Figure 4. Inﬂuence of blending time at blending speed of 25 rpm on the distribution of magnesium on
the surface of particles.
Figure 5. Inﬂuence of blending speed on the distribution of magnesium at a blending time 5min.
Table 1. Parameters of surface properties of particles.
First material
Second
material
SE1
(mN/m)
Sd1
(mN/m)
Sp1
(mN/m)
SE2
(mN/m)
Sd2
(mN/m)
Sp2
(mN/m)
Wa
(mJ/m2)
S1,2
(mN/m)
Mgst (high spec.
surface area)
Levodopa 22.68 22.68 0 84.87 49.05 35.82 62.04 16.68
Benserazide 22.68 22.68 0 82.85 47.10 35.75 61.23 15.87
Granule 22.68 22.68 0 82.10 48.28 33.82 61.72 16.36
Mgst (small spec.
surface area)
Levodopa 32.18 27.93 4.25 84.87 49.05 35.82 86.38 22.02
Benserazid 32.18 27.93 4.25 82.85 47.10 35.75 85.33 20.97
Granule 32.18 27.93 4.25 82.10 48.28 33.82 85.88 21.52
Note: SE= total surface free energy, Sd= disperse part of free energy, Sp= polar part of free energy, Wa = adhesion
work, S12= spreading coefﬁcient.
6 I. Jójárt et al.
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coefﬁcient. Since the magnesium stearate with higher speciﬁc surface area is totally apolar it
has fewer binding points on the surface of the particles, whereas the magnesium stearate with
lower speciﬁc surface area can bind only to polar binding points. In this case, the use of mag-
nesium stearate with lower speciﬁc surface area is more advantageous.
Since the spreading coefﬁcient value (S12) is positive, magnesium stearate (material 1)
spreads on the surface of the other components (material 2). The more positive the S12, the
better the spreading. It must be noted that the spreading of the magnesium stearate with lower
speciﬁc surface area is better and the adhesion work of these samples is higher than for the
samples containing magnesium stearate with higher speciﬁc surface area.
4. Conclusions
It can be concluded that the two types of magnesium stearate were distributed to different
extents on the surface of the particles. The magnesium stearate with higher speciﬁc surface
area was more polar with higher adhesion work, and it was able to create a very thin homo-
geneous layer on the surface of the particles. In the case of the magnesium stearate with
lower speciﬁc surface area, enrichment was observed on the surface of the particles, decreas-
ing the free energy.
It is clear that the surface free energy and polarity of the materials inﬂuence the choice of
the suitable magnesium stearate (low or high speciﬁc surface). It can be stated that the blend-
ing speed should not be too high because at longer mixing time the free energy of the other
component will be dominant (see Figure 4).
Energy-dispersive X-ray ﬂuorescence analysis was successfully used for the in-process
determination of the distribution of magnesium stearate on the surface of the particles. The
measurement was rapid and did not require any special sample preparation.
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III. 
1Introduction
Chewing gum has been used world-wide since ancient 
times when man experienced the pleasure of chewing a 
variety of gum-like substances, such as tree resins, leaves, 
waxes and animal skins.
e dosage form or delivery system is critical for the 
success of a pharmaceutical or a food product. Today, 
chewing gum is undergoing new consideration as a drug 
delivery system; it provides patient benet and compli-
ance, and has new competitive advantages from the 
technological and marketing aspects. Medicated chewing 
gums are solid, single-dose preparations that have to be 
chewed but not swallowed. Chewing gums contain one 
or more active pharmaceutical ingredients (APIs) that 
are released by chewing (Ph.Eur.).[1] A medicated chew-
ing gum is intended to be chewed for a certain period of 
time, required to deliver the dose, after which the remain-
ing mass is discarded.[2, 3] During the chewing process, 
the drug contained in the gum product is released from 
the mass into the saliva and can be absorbed through the 
oral mucosa or swallowed, reaching the stomach for gas-
trointestinal absorption.
Chewing gum consists basically of a neutral and taste-
less masticatory gumbase and several non-masticatory 
ingredients, such as llers, softeners, sweeteners, favoring 
and texture regulating agents.[1, 4] e gum bases currently 
used are mostly of synthetic origin and comprised of elasto-
mers, resins, waxes, fats and emulsiers. e elastomers are 
styrene–butadiene copolymers mixed with polyisobutene. 
e addition of rosin esters and polyvinyl acetate improves 
the texture, allows longer-lasting avor and reduces the ten-
dency of the gum to stick to the teeth. Other agents, such as 
glycerol monostearate and lecithin, act as emulsiers and 
promote the uptake of saliva during chewing.[5]
Powdered sugar and corn syrup were originally used as 
bulk sweeteners; nowadays, a mixture of sorbitol, xylitol, 
mannitol and aspartame is more commonly used in sug-
ar-free, non-cariogenic gums and medicinal products.[6]
Unfortunately, the thermal instability of many active 
ingredients (vitamins, vegetable extracts, etc.) precludes 
traditional chewing gum production methods because 
the temperature proles associated with this type of pro-
duction may reach 90°C.[7]
Recently, chewing gums produced by direct compres-
sion have been proposed.[8] With this conventional tablet 
compression technology, these chewing gums can include 
higher levels of active ingredients than in traditional 
extruded gums; the lower temperature protects sensitive 
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bioactive and phytochemical components and the lower 
moisture content improves the shelf-life of active molecules. 
However, the most common drawback in direct compres-
sion of the gum base is that it sticks to the punches of the 
tableting equipment. !is is due to the adhesive nature of 
the gum, the main component of the formulation; for this 
reason, the procedure is di"cult and needs a lower pro-
duction speed and cooling operations in order to prevent 
tableting machine damage. !e tableting tools are kept at 
temperatures below 18°C; however, it should be noted that 
the temperature should not be so low as to interfere with the 
handling of the medicated gums and the tableting process. 
!us, the temperature should be above 10–12°C.
For investigation of the dissolution of active pharma-
ceutical ingredients (API’s) from medicated chewing gum 
tablets, di$erent apparatuses have been developed. !e 
chewing equipment applied was developed by Erweka 
GmbH, and described by Kvist et al.[9] Further descrip-
tions of dissolution and chewing gum tablet investiga-
tions have been reported by Azarmi et al.[10]
!e objective of this work was to study the compression 
and breaking processes of di$erent gum bases at room 
temperature by a direct compression technique with con-
ventional pharmaceutical equipment e"ciently providing 
the product, and to investigate the dissolution of an API.
Materials and methods
Materials
Ascorbic acid was used as model material (Ph. Eur.). 
Pharmagum C, M and S (gifts from SPI Pharma) were 
used as gum bases. Pharmagum M has a 50% greater 
gum base than Pharmagum S, which consists primarily 
of gum base and sorbitol. Pharmagum M contains gum 
base, mannitol and isomalt.
According to the manufacturer data, Pharmagum S is 
suitable for formulations with low drug loading and when 
incorporated into tablets gives them chewable character. 
Pharmagum M is suggested for medium drug loading 
(<50%); it improves the mouthfeel texture. Pharmagum 
C is suggested for high drug loading (>50%); it has a real 
chewing gum character.
Pharmagum mixtures were prepared in di$erent 
ratios to study the compactness and deformability 
(Table 1). Compactness means the permanent bindings 
which are formed during loading and deformability refers 
to the shape modi&cation of the particles during loading. 
Besides ascorbic acid as API, additional components of 
the mixtures were xylitol (frequently used in tablets as 
a sweetener), magnesium stearate (as a lubricant) and 
aroma (to give the tablets a better smell).
Methods
Tableting
!e tablets were prepared with a Korsch EK0 eccentric 
tableting machine, E. Korsch Maschinenfabrik, Germany. 
!e compression tools were *at-faced, bevel-edged punches 
10 mm in diameter and equipped with strain gauges and a 
displacement transducer. !e strain gauges allowed the pres-
sure forces on the upper and lower punches to be followed 
with force-measuring equipment, which was calibrated 
with a Wazau HM-HN-30kN-D cell (Kaliber Ltd., Budapest, 
Hungary). !e displacement transducer (Micropulse, BTL5-
A11-M0050-P-532, Ballu$, Neuhausen/Filder, Germany) 
was &tted over the upper punch. !e transducer distance 
accuracy was checked by using &ve measuring pieces of dif-
ferent accurately known thicknesses (2.0, 5.0, 7.5, 10.0 and 
15.0 mm) under zero load (Mitutoyo, Tokyo, Japan). !e 
compression was carried out electrically at 36 rpm, at an air 
temperature of 24°C and at a relative air humidity of 45%. 
!e average mass of the tablets was 0.47 ± 0.01 g. Ten tablets 
were compressed at compression forces of 5, 7.5, 10, 12.5 
and 15 kN for each sample (when possible). Lots with rela-
tive standard deviations not exceeding 5% were accepted.
!e force–displacement curves were plotted, and the 
compression parameters − e$ective work (E
2
), elastic 
recovery (E
3
) and plasticity (P
l
) − were calculated from 
the curves with our own software Kása et al.[11]
!e E
1
, E
2
 and E
3
 energies are calculated by the follow-
ing equations:
E
F C
E E1 2 3
2
? ? ?max ( ) (1)
E F ds E
A
B
2 3? ?? upper (2)
E F ds
B
D
3 ? ? upper (3)
 where
F
max
 = maximum force during compressing; C = dis-
placement; F
upper
 = maximum force measured on the 
upper punch; ds = elemental value of the displacement.
!e plasticity was calculated with the formula: Pl = E2 
/ E2 + E3.
Table 1. Compositions of powder mixtures.
 Pharmagum (%)
 C M S
S 1 60 40  
S 2 50 50  
S 3 40 60  
S 4 60  40
S 5 50  50
S 6 40  60
S 7  60 40
S 8  50 50
S 9  40 60
!e amounts of the following materials were the same in all  
cases (%)
Ascorbic acid 8.33   
Xylitol 7.68   
Aroma 0.33   
Magnesium stearate 2   
API concentration: 33 mg/tablet.
Average tablet weight: 0.47 g.
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e real force–displacement diagram can be seen in 
Figure 1. (S1 sample) where E
1
 = 44.58%, E
2
 = 46.22% and 
E
3
 = 9.21%.
Friability test
e friability of the chewing gum tablets was tested 
with an Erweka TA 100 friabilator (Erweka GmbH, 
Heusenstamm, Germany).
Breaking strength
e breaking strength was tested with a self-developed 
tablet hardness tester, which is connected to a computer 
and a special software is applied to edit the force–time 
diagram.
Technical parameters of the hardness tester:
Range of measurement: 0–200 N??
Rate of pressing jaw: 20 mm/min??
Registration output: 0–500 mV??
Force sensor: Unicell load cell (MIKI) 200 N??
Preparation of mixtures
e mixtures of two of the Pharmagum materials in vari-
ous ratios were prepared with a Turbula mixer (Willy A 
Bachofen, Switzerland) at 50 rpm for 8 min, after which 
the other components were added, and mixing was con-
tinued for a further 2 min (Table 2). e mass of each 
powder mixture was 200 g.
Dissolution test
Conventional tablet or capsule dissolution testers are not 
applicable for the investigation of chewing gum tablets 
because of the nature of the preparation. Solid oral dosage 
forms are generally swallowed and the API subsequently 
dissolves in various parts of the gastrointestinal tract. 
Chewing gum tablets are usually not swallowed but mas-
ticated, and the API dissolves in a very small amount of 
dissolution medium. e e!ective material does not come 
into direct contact with the stomach, but must dissolve in 
the saliva. After dissolution, the saliva is swallowed and 
only a diluted quantity of the API reaches the gastric juice.
For the dissolution tests, an Erweka chewing appara-
tus was used.[9] Each chewing gum sample was chewed 
with this apparatus for 10, 20 or 30 min, in the presence 
of 20 of dissolution medium (puri"ed water), after which 
the ascorbic acid content of the liquid was determined by 
spectrometry.
Figure 1. Recorded force–displacement diagram of S1 sample.
Table 2. Powder rheological test.
 
Material of the 
funnel Flowing time (s)
Agitation speed  
(r/min) Angle of slope (°)
Heap volume  
(ml) Heap mass (g)
Ascorb. acid T 12.3 25 33.1 85.6 77.8
Phg C T/M – – – – –
Phg M T/M – – – – –
Phg S T  7.5 25 26.2 64.4 56.6
S 1 M 12.3 10 29.3 73.4 58.8
S 2 M 10.3 10 29.4 73.9 59.7
S 3 M 10.0 10 29.8 75.0 58.8
S 4 M  7.6  5 26.6 65.6 66.9
S 5 M  7.3 10 27.5 68.2 67.8
S 6 M  7.4 10 28.3 70.6 65.5
S 7 M  8.3 10 29.1 73.0 66.4
S 8 M  8.4 10 28.4 70.9 68.6
S 9 M  8.1 10 28.1 71.5 69.3
M, metal; T, te"on.
− = not measurable.
Table 3. Compressionability of the mixtures.
 B.d. g/cm3 T.d. g/cm3 C.i. % Tr.d. g/cm3
S 1 0.59 0.64 8.72 1.31
S 2 0.58 0.64 10.00 1.31
S 3 0.59 0.64 7.95 1.32
S 4 0.68 0.74 8.46 1.33
S 5 0.71 0.76 5.38 1.33
S 6 0.70 0.74 4.88 1.33
S 7 0.70 0.73 4.61 1.32
S 8 0.70 0.75 5.90 1.33
S 9 0.72 0.77 6.41 1.33
B.d., bulk density; C.i., Carr’s index; T.d., tapped density; Tr.d., 
true density.
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Results and discussion
e tests on the ow properties of the bulk gum samples 
showed that Pharmagum C and M could not ow out from 
either a teon or a metal funnel, in spite of the agitation 
of the powder. Pharmagum S displayed good owability 
from a teon funnel on mixing at 25 rpm (Table 3). e 
API owed from a teon funnel on agitation at 25 rpm.
e compaction tests on the bulk materials resulted 
in every case in high elastic recovery (Table 4). As con-
cerns tablettability, the owability and compactness can 
be important properties. Solid bridges formed during 
compression phase can be broken in the elastic recovery 
phase. In the tablet compositions, therefore the bulk gum 
powders were mixed with the other components in dif-
ferent ratios (Table 1).
Table 4. E!ect of compression force on elasticity and friction for 
bulk gum bases.
Sample F
upper
 (kN) FW (J) E
3
 (J)
Gum C 5 0.022 0.43
10 0.037 1.35
15 0.047 3.61
Gum M 5 0.003 0.25
10 0.013 1.24
15 0.066 2.90
Gum S 5 0.100 0.49
10 0.138 1.12
15 0.162 3.91
FW shows the work which arises during the tablet ejection.
E
3
 shows the elastic recovery.
Figure 2. Relationship between the Pressure force and Elastic recovery. (See colour version of this gure online at www.informahealthcare.
com/phd)
Table 5. Relationship between compositions and E
3
 areas.
Sample
Compositions  
(Gum base) E
3
 (J) Compression forces (kN)
C M S 5 7.5 10 12.5 15
S 1 60 40 – 0.48 1.07 1.69 2.51 3.36
S 2 50 50 – 0.42 1.10 1.76 2.16 2.59
S 3 40 60 – 0.36 0.98 1.56 2.04 2.60
S 4 60 – 40 0.70 1.30 1.84 2.30 2.72
S 5 50 – 50 0.62 1.07 1.52 2.26 2.89
S 6 40 – 60 0.67 1.05 1.49 2.19 3.05
S 7 – 60 40 0.56 1.03 1.55 2.36 3.01
S 8 – 50 50 0.61 1.05 1.55 2.27 3.02
S 9 – 40 60 0.58 1.06 1.56 2.29 3.02
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e data in Table 3 reveal that the powder mixtures could 
!ow from a metal funnel on moderate stirring. Mixture S4, 
which contains Pharmagum S, exhibited the best !owabil-
ity to which an agitation speed of only 5 rpm was applied. 
e !owability properties of the mixtures containing 
Pharmagum S were generally better. ese data are in 
accordance with the other powder rheological parameters.
e Carr index, calculated from the bulk and tapped 
densities, indicates that the powder mixtures have excel-
lent compressibility (Table 3). However the mixtures 
adhered to the punches during tableting, which is an unfa-
vorable property. Fortunately, this could be eliminated 
through the use of a te!on lm on the punch surface.
e di#erent compression parameters for the mixtures 
were calculated at di#erent compression forces (e#ective 
work = E
2
, elastic recovery = E
3
, plasticity = P
l
).
For gums, elasticity is the most important property. 
After the compression maximum, when the upper punch 
starts to move upwards, elastic materials display some 
recovery. e degree of elastic recovery varied linearly 
with the compression force (y = ax + b, where y = E
3
, 
a = slope, x = compression force, and b = intercept), with 
a very good correlation (R2 = 0.984–0.999) (Figure 2). 
Further, the degree of elastic recovery increased in all 
mixtures after compression (Table 5). Pharmagum M 
in!uenced the elastic recovery to the highest degree. S1, 
S2 and S3 tablets had the smallest E
3
 values at a compres-
sion force of 5 kN and these values decreased linearly 
with increasing Pharmagum M content. (from the aspect 
of tableting, the smallest E
3
 value is advantageous.) For 
S2 and S3 tablets, the decreases in E
3
 were smaller, and 
at 10 and 15 kN the Pharmagum M and C ratios of 50:50 
and 40:60 had practically no e#ect on the E
3
 values. For 
the other mixtures, the ratio usually had very little e#ect 
on the degree of elastic recovery at di#erent compression 
forces, except for the S6 mixture compressed at 15 kN. 
e elastic properties of the API and other ingredients do 
not have such high e#ect which causes any changes of 
the elastic behavior of the gum bases.
e friability of the tablets was less than 0.1% in all 
cases, and they met the requirements of Ph.Eur., but this 
is expected from a gum tablet. Another postcompression 
test involves the breaking strength; this di#ers from the 
case of conventional tablets because after crushing the 
tablets did not break completely. e deformation curves 
during loading demonstrate elastic deformation with a 
rather high slope (Figure 3). After a maximum, the force 
decreased, but the tablet did not break into small pieces; 
only deformation was observed, with some cracks. 
Increase of the pressure did not cause any signicant 
changes in the breaking process. If the E
3
 value is low the 
deformation force is high, which means that the appro-
priate chewability needs a higher force.
During the dissolution investigation the 5, 10, and 
15 kN, compressed samples were tested. e results show 
that the dissolution of ascorbic acid did not depend on 
the compression force (Figure 4). In all cases, 90% of the 
API dissolved in the rst 10 min, and after chewing for 
30 min the whole amount had dissolved.
Conclusions
e powder rheological parameters, and especially the 
!owability, conclude that Pharmagum C and M are 
not suitable for the preparation of direct-compressed 
chewing gum tablets. Pharmagum S increased the pow-
der rheological properties and the compressibility, but 
all of the compositions resulted in suitable tablets at 
a compression force of 5 kN. e physical parameters 
and the dissolution rate from these tablets were very 
good, so that increase of the compression force was 
unnecessary.
Finally, it can be stated that chewing gum is an alter-
native drug delivery system with several advantages 
especially for kids and geriatric patients who experience 
di$culties swallowing the traditional oral solid dosage 
forms, and it is possible to prepare by direct compres-
sion, which is economic preparation procedure.
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a b s t r a c t
The elasticity and elastic recovery of chewing gum powder were tested in this work. Powder rheological
tests (flowability and compressibility) showed that direct compression is a suitable method for the prep-
aration of chewing gum tablets. The advantages of this method relative to preparation by extrusion are
economic: a reduced processing time, fewer manufacturing steps, less equipment, less process validation
and reduced labour costs.
A very important property of a chewing gum tablet is the chewability, which depends on the elasticity
of the product. This was tested by breaking strength measurements and study of the deformation process.
For a good chewable tablet, the authors suggest application of a compression force of 5 kN.
Ó 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Chewing gum is currently receiving increasing consideration as a
drug delivery system. Medicated chewing gums are solid, single-
dosepreparations that have tobe chewedandnot swallowed; chew-
ing gums contain one ormore active ingredients that are released by
chewing.Medicated chewing gums aremadewith a tastelessmasti-
catory gum base that consists of natural or synthetic elastomers.
They may contain other excipients, such as fillers, softeners, sweet-
ening agents, flavouring substances, stabilizers, plasticizers and
authorized colouring matter (European Pharmacopoea (Ph. Eur.)).
Chewing gums produced by direct compression have recently
been proposed [1]. With conventional tablet compression technol-
ogy, these chewing gums can include higher levels of active ingredi-
ents than those in traditional extrudedgums, the lower temperature
protects sensitive bioactive and phytochemical components, and
the lower moisture content improves the shelf-life of active mole-
cules. However, the most common drawback of the direct compres-
sion of the gum base is that it sticks to the punches of the tableting
equipment. This is due to the adhesive nature of the gum, the main
component of the formulation; for this reason, the procedure is
rather difficult and demands a lower production speed and cooling
operations in order to prevent tableting machine damage. From a
formulation aspect, it is very important to know the properties of
compressed tablets.
The objective of the present work was to study the elastic
recovery of a gum base prepared at room temperature by a direct
compression technique, by means of thickness, diameter and hard-
ness measurements.
2. Background
As a result of the elastic recovery, the structure of tablets after
compression exhibits various phenomena, which change the vol-
ume and the porosity. The driving forces for elastic recovery are
the bonding forces (i.e. van der Waals forces, solid bridges, electro-
static forces, hydrogen-bonds, etc.) and the elastic energy (stress)
stored in the particles during densification. The stored stress can
be released, and increase the tablet volume and porosity. However,
the bonding forces which are associated with the stress simulta-
neously decrease the tablet volume and porosity. The elastic recov-
ery (ER) can be defined as the following equation:
ER ¼
V t ÿ Vmin
Vmin
ð1Þ
The elastic recovery provides information on the residual elas-
ticity of the given material [2]. The degree of elastic recovery de-
pends on the properties of the materials. Elastic recovery starts
immediately after the compression phase and is completed after
several days, the duration depending on the material.
The definition of tablet hardness is generally accepted as the
force required to break a tablet in a diametrical compression test.
To measure the force required to break a tablet, we determined
the tensile strength of the tablet via the following expression [3]:
rx ¼
2  F
p  d  t
ð2Þ
1359-8368/$ - see front matter Ó 2013 Elsevier Ltd. All rights reserved.
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3. Materials and methods
3.1. Materials
A directly compressible gum composition was used as model
material (Health in Gum) (CAFOSA GUM, S.A.U., Barcelona, Spain)
(Table 1).
All the materials used (excluding the gum base) in this product
comply with their Ph. Eur. and USP monographs. All the materials
used in the gum base comply with the USA Food and Drug Admin-
istration, Code of Federal Regulations, title 21, sect. 172.615 and
Food Chemicals Codex Specifications.
3.2. Methods
3.2.1. Flow properties and moisture content
The flow properties of the gum powder were determined with a
PharmaTest PTG-1powder rheological tester (PharmaTestApparte-
bau, Germany).
The compaction behaviour of the materials was tested with an
Engelsmann stampfvolumeter (J. Engelsmann A-G, Ludwigshafen,
Germany).
Themoisture content of the gum powder was determined with a
moisture analyzer (HR73 Halogen Moisture Analyzer, Mettler-To-
ledo GmbH, Greifensee, Switzerland). The standard drying program
was used, with a drying temperature of 105 °C. The sample was
heated to 105 °C and then held constant at that temperature. The
powder was dried to constant mass.
Three parallel experiments were performed.
3.2.2. Tableting
The tablets were prepared with a Korsch EK0 eccentric tableting
machine. The compression tools were flat-faced bevel-edged
punches 10 mm in diameter and equipped with strain gauges
and a displacement transducer. The strain gauges allowed the pres-
sure forces on the upper and lower punches to be followed with
force-measuring equipment, which was calibrated with a Wazau
HM-HN-30kN-D cell (Kaliber Ltd., Budapest, Hungary). The
displacement transducer (Micropulse, BTL5-A11-M0050-P-532,
Balluff, Neuhausen/Filder, Germany) was fitted over the upper
punch. The transducer distance accuracy was checked by using five
measuring pieces of different accurately known thicknesses (2.0,
5.0, 7.5, 10.0 and 15.0 mm) under zero load (Mitutoyo, Tokyo, Ja-
pan). The compression was carried out electrically at 36 rpm, at
an air temperature of 24 °C and a relative air humidity of 45%.
The average mass of the tablets was 0.40 ± 0.02 g. 150 tablets were
compressed at compression forces of approximately 5, 10, 12.5 and
15 ± 1 kN. Lots with relative standard deviations not exceeding 5%
were accepted. The force–displacement curves were plotted, and
the different energy/work relations were calculated from the
curves with our own software [4].
The tablets were stored in airtight plastic containers, at an air
temperature of 24 °C and a relative air humidity of 45%.
3.2.3. Breaking strength
The breaking process was tested with a modified breaking hard-
ness tester, which was connected to a computer, and special own-
developed software was applied to record the force–time diagram.
The tester contained a specimen holder and a jowl, and was
connected to a computer via an interface. The specimen was lo-
Table 1
Composition of the gum powder.
Material Amount (%)
Gum base 28–32
Sorbitol Up to 100
Xylitol 8–12
Plasticizer <1.5
Antitacking agent (E-551) <2.0
Fig. 1. Volume changes of the comprimates.
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cated horizontally on a special plate and the jowl moved vertically.
Twenty parallel measurements were performed.
The measurement range was 0–200 N, the speed of the stamp
was 20 mm/min and the output was 0–5 V. The sensor was a Uni-
cell force-measuring instrument (MIKI), calibrated with the C9B
20 kN cell.
3.2.4. Geometrical parameter measurements
The height and the diameter of the tablets were measured with
a digital micrometer (Mitutoyo, Tokyo, Japan). The measured and
the calculated average values were printed out. Twenty tablets
were measured for each sample. The average tablet volume was
determined according to the following equation:
V ¼ t
d
2
 2
p ð3Þ
where t is the thickness, and d is the diameter.
The geometrical parameters were measured at the following
sampling times: directly after compression, and after storage times
of 1, 4, 8 and 24 h and 2, 3, 4, 5, 6 and 7 days following tablet press-
ing. (In view of the large number of data, only selected data on the
fresh tablet and the data after 1 and 7 days of storage are presented
in the tables.)
4. Results and discussion
Moisture content determination is an important preformulation
test before tableting. It influences the flow properties of granules or
powders, which must flow freely into the die cavity during tablet-
ing. The Hausner factor and Carr’s index are calculated from the
poured and tapped densities of the powder. A Hausner factor of less
than 1.25 (equivalent to a Carr’s index of 20%) indicates good flow;
when it is greater than 1.5 (a Carr’s index of 33%), it indicates poor
flow. The moisture content of the gum powder was rather low
(0.3%), and the flowability was very good (flow time: 8.4 s). This
means that the gum powder could flow freely in the die during
the compression. The values of the Hausner factor (1.102) and Carr’s
(Carri = 9.23%) showed that the arrangement of the particles was
also good [5].
It is clear from the tablet volume changes (Fig. 1) that the appli-
cation of higher compression forces imposes too much on the gum
stress during storage. When the compression force is higher than a
certain limit, the gum loses its elasticity. As noted above, the driv-
ing forces for the final stage of tablet formation are the bonding
forces and the stress stored in the gum. The gum strives to release
the stored stress by increasing the volume of the tablet, while the
bonding forces decrease the volume. This phenomenon is very well
observable at pressure force of 5, 10 and 12.5 kN (Fig. 1). At 15 kN,
the gum loses its elasticity and thus the main driving forces in the
final formation stage are the bonding forces.
The geometrical parameters of the tablets can be seen in Table
2. The post-compressional geometrical changes in the tablets must
be taken into consideration, especially in blister packaging. In this
case, the geometrical parameters determine the depth and diame-
ter of the blister cavity.
It can be concluded from the data that both the diameter and
the thickness of the tablets decreased continuously during 7 days
Table 2
Geometrical parameters of tablets.
Compression force
(kN)
Diametera (mm) Thickness (mm)a
Fresh 1 day 7 days Fresh 1 day 7 days
5 10.030 10.010 9.997 4.242 4.217 4.206
10 10.041 10.021 10.005 4.136 4.142 4.120
12.5 10.044 10.027 10.013 4.155 4.139 4.135
15 10.044 10.025 10.021 4.172 4.151 4.150
a SD < ±5%.
Table 3
Tablet strength data.
Compression force (kN) Breaking strengtha (N) Tensile strengtha (MPa)
Fresh 1 day 7 days Fresh 1 day 7 days
5 60 70 85 0.90 1.05 1.29
10 59 61 74 0.90 0.93 1.15
12.5 55 61 76 0.84 0.94 1.17
15 55 61 77 0.84 0.94 1.18
a SD < ±5%.
Fig. 2. Breaking process for fresh tablets.
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of storage, but the degree of contraction differed. This is reflected
in the volume changes.
The testing of the mechanical strength of the tablets is very
important because they must remain intact during handling, i.e.
packaging and transportation. The mechanical characterization of
different materials and preparations is investigated in different sci-
entific fields [6–8]. In our work the breaking strength of the prep-
aration was studied. The data are summarized in Table 3. It can be
seen that the greatest strengths were measured in every case at a
compression force of 5 kN, and the breaking strength increased
during storage. With increase of the compression force, the tablets
exhibited lower strength and the increases in strength during stor-
age were more moderate. It is noteworthy that the tablet strengths
at 12.5 and 15 kN were almost the same in every situation.
Investigation of the breaking hardness of direct compressed
chewing gum tablets is important not only for determination of
their general parameters, but also from the aspect of the user’s sat-
isfaction. The preparations should provide adequate strength and
ease of processability, and the consumer should find them pleasant
and easy to use. It is not necessary to apply an extremely high com-
pression force to prepare a good chewing gum tablets, because this
will not cause any significant difference in quality.
Fig. 3. Tablet breaking process after storage for 1 day.
Fig. 4. Tablet breaking process after storage for 7 days.
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Determination of the breaking (deformation) force is important
because it is necessary to know what energy is needed to break the
chewing gum tablet. If the compression force is too high, the gum
will not acceptable by the patient, but if it is too low, the tablet will
not be formed during compression.
The breaking process, which reflects the elastic/plastic behav-
iour of the tablet after compression, occurred in accordance with
the volume changes. With increase of the compression force, the
degree of elasticity decreased (Figs. 2–4). The action of the com-
pression force can be observed very well in the case of fresh tablets
(Fig. 2). The degree of elastic recovery was highest for tablets com-
pressed at 5 kN, but the linear section of the deformation curve was
not too long and soft-viscous (viscoelastic) deformation occurred.
After storage for 1 day, the tablet compressed at 5 kN exhibited
a higher elastic nature because the macromolecules underwent
rearrangement within 1 day (Fig. 3). The deformation profiles of
the other tablets did not reveal a significant change. Practically
no difference could be observed between the curves. Despite the
increase in the deformation maximum of the tablet compressed
at 5 kN, the shape of the deformation curves did not change during
storage (Fig. 4).
5. Conclusions
Overall, it can be concluded that the flowability of Cafosa gum
powder is very good and its direct compression is possible. The
post-compressional tests demonstrated that a compression force
of 5 kN is sufficient for preparation. The elastic behaviour of these
tablets is the best from the aspect of the chewability. The advantage
of these tablets is that the patient can chew such a tablet easily and
the drug can be released in the mouth. The drug can then be swal-
lowed and pass into the stomach or intestine or may be absorbed
through the mucosa and a rapid drug effect will be obtained.
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